<!doctype html>
<html class="">
	<head>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no" />
		<meta name="description" content="Weâ€™re on a journey to advance and democratize artificial intelligence through open source and open science." />
		<meta property="fb:app_id" content="1321688464574422" />
		<meta name="twitter:card" content="summary_large_image" />
		<meta name="twitter:site" content="@huggingface" />
		<meta name="twitter:image" content="https://cdn-thumbnails.huggingface.co/social-thumbnails/datasets/jaydeyoung/evidence_infer_treatment.png" />
		<meta property="og:title" content="jaydeyoung/evidence_infer_treatment Â· Datasets at Hugging Face" />
		<meta property="og:type" content="website" />
		<meta property="og:url" content="https://huggingface.co/datasets/jaydeyoung/evidence_infer_treatment" />
		<meta property="og:image" content="https://cdn-thumbnails.huggingface.co/social-thumbnails/datasets/jaydeyoung/evidence_infer_treatment.png" />

		<link rel="stylesheet" href="/front/build/kube-68d7aa0/style.css" />

		<link rel="preconnect" href="https://fonts.gstatic.com" />
		<link
			href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,200;0,300;0,400;0,600;0,700;0,900;1,200;1,300;1,400;1,600;1,700;1,900&display=swap"
			rel="stylesheet"
		/>
		<link
			href="https://fonts.googleapis.com/css2?family=IBM+Plex+Mono:wght@400;600;700&display=swap"
			rel="stylesheet"
		/>

		<link
			rel="preload"
			href="https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.12.0/katex.min.css"
			as="style"
			onload="this.onload=null;this.rel='stylesheet'"
		/>
		<noscript>
			<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.12.0/katex.min.css" />
		</noscript>

		<script>const guestTheme = document.cookie.match(/theme=(\w+)/)?.[1]; document.documentElement.classList.toggle('dark', guestTheme === 'dark' || ( (!guestTheme || guestTheme === 'system') && window.matchMedia('(prefers-color-scheme: dark)').matches));</script>
<link rel="canonical" href="https://huggingface.co/datasets/jaydeyoung/evidence_infer_treatment"> <script type="application/ld+json">{
  "@context": "https:\/\/schema.org",
  "@type": "Dataset",
  "name": "evidence_infer_treatment",
  "description": "Data and code from our \"Inferring Which Medical Treatments Work from Reports of Clinical Trials\", NAACL 2019. This work concerns inferring the results reported in clinical trials from text.\n\nThe dataset consists of biomedical articles describing randomized control trials (RCTs) that compare multiple treatments. Each of these articles will have multiple questions, or 'prompts' associated with them. These prompts will ask about the relationship between an intervention and comparator with respect to an outcome, as reported in the trial. For example, a prompt may ask about the reported effects of aspirin as compared to placebo on the duration of headaches. For the sake of this task, we assume that a particular article will report that the intervention of interest either significantly increased, significantly decreased or had significant effect on the outcome, relative to the comparator.\n\nThe dataset could be used for automatic data extraction of the results of a given RCT. This would enable readers to discover the effectiveness of different treatments without needing to read the paper.",
  "alternateName": [
    "jaydeyoung\/evidence_infer_treatment",
    "Evidence Infer Treatment"
  ],
  "creator": {
    "@type": "Person",
    "name": "jay deyoung",
    "url": "https:\/\/huggingface.co\/jaydeyoung"
  },
  "keywords": [
    "text-retrieval",
    "fact-checking-retrieval",
    "expert-generated",
    "expert-generated",
    "monolingual",
    "original",
    "English",
    "mit",
    "1K\u003cn\u003c10K",
    "arxiv:2005.04177",
    "ðŸ‡ºðŸ‡¸ Region: US"
  ],
  "license": "https:\/\/choosealicense.com\/licenses\/mit\/",
  "sameAs": "http:\/\/evidence-inference.ebm-nlp.com\/",
  "url": "https:\/\/huggingface.co\/datasets\/jaydeyoung\/evidence_infer_treatment"
}</script> 

		<title>jaydeyoung/evidence_infer_treatment Â· Datasets at Hugging Face</title>

		<script
			defer
			data-domain="huggingface.co"
			event-loggedIn="false"
			src="/js/script.pageview-props.js"
		></script>
		<script>
			window.plausible =
				window.plausible ||
				function () {
					(window.plausible.q = window.plausible.q || []).push(arguments);
				};
		</script>
		<script>
			window.hubConfig = {"features":{"signupDisabled":false},"sshGitUrl":"git@hf.co","moonHttpUrl":"https:\/\/huggingface.co","captchaApiKey":"bd5f2066-93dc-4bdd-a64b-a24646ca3859","captchaDisabledOnSignup":true,"datasetViewerPublicUrl":"https:\/\/datasets-server.huggingface.co","stripePublicKey":"pk_live_x2tdjFXBCvXo2FFmMybezpeM00J6gPCAAc","environment":"production","userAgent":"HuggingFace (production)","spacesIframeDomain":"hf.space","spacesApiUrl":"https:\/\/api.hf.space","docSearchKey":"ece5e02e57300e17d152c08056145326e90c4bff3dd07d7d1ae40cf1c8d39cb6","logoDev":{"apiUrl":"https:\/\/img.logo.dev\/","apiKey":"pk_UHS2HZOeRnaSOdDp7jbd5w"}};
		</script>
		<script type="text/javascript" src="https://de5282c3ca0c.edge.sdk.awswaf.com/de5282c3ca0c/526cf06acb0d/challenge.js" defer></script>
	</head>
	<body class="flex flex-col min-h-dvh bg-white dark:bg-gray-950 text-black DatasetPage">
		<div class="flex min-h-dvh flex-col"><div class="SVELTE_HYDRATER contents" data-target="SystemThemeMonitor" data-props="{&quot;isLoggedIn&quot;:false}"></div>

	<div class="SVELTE_HYDRATER contents" data-target="MainHeader" data-props="{&quot;classNames&quot;:&quot;&quot;,&quot;isWide&quot;:false,&quot;isZh&quot;:false,&quot;isPro&quot;:false}"><header class="border-b border-gray-100 "><div class="w-full px-4 container flex h-16 items-center"><div class="flex flex-1 items-center"><a class="mr-5 flex flex-none items-center lg:mr-6" href="/"><img alt="Hugging Face's logo" class="w-7 md:mr-2" src="/front/assets/huggingface_logo-noborder.svg">
				<span class="hidden whitespace-nowrap text-lg font-bold md:block">Hugging Face</span></a>
			<div class="relative flex-1 lg:max-w-sm mr-2 sm:mr-4 md:mr-3 xl:mr-6"><input autocomplete="off" class="w-full dark:bg-gray-950 pl-8 form-input-alt h-9 pr-3 focus:shadow-xl " name="" placeholder="Search models, datasets, users..."   spellcheck="false" type="text" value="">
	<svg class="absolute left-2.5 text-gray-400 top-1/2 transform -translate-y-1/2" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M30 28.59L22.45 21A11 11 0 1 0 21 22.45L28.59 30zM5 14a9 9 0 1 1 9 9a9 9 0 0 1-9-9z" fill="currentColor"></path></svg>
	</div>
			<div class="flex flex-none items-center justify-center p-0.5 place-self-stretch lg:hidden"><button class="relative z-40 flex h-6 w-8 items-center justify-center" type="button"><svg width="1em" height="1em" viewBox="0 0 10 10" class="text-xl" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" preserveAspectRatio="xMidYMid meet" fill="currentColor"><path fill-rule="evenodd" clip-rule="evenodd" d="M1.65039 2.9999C1.65039 2.8066 1.80709 2.6499 2.00039 2.6499H8.00039C8.19369 2.6499 8.35039 2.8066 8.35039 2.9999C8.35039 3.1932 8.19369 3.3499 8.00039 3.3499H2.00039C1.80709 3.3499 1.65039 3.1932 1.65039 2.9999ZM1.65039 4.9999C1.65039 4.8066 1.80709 4.6499 2.00039 4.6499H8.00039C8.19369 4.6499 8.35039 4.8066 8.35039 4.9999C8.35039 5.1932 8.19369 5.3499 8.00039 5.3499H2.00039C1.80709 5.3499 1.65039 5.1932 1.65039 4.9999ZM2.00039 6.6499C1.80709 6.6499 1.65039 6.8066 1.65039 6.9999C1.65039 7.1932 1.80709 7.3499 2.00039 7.3499H8.00039C8.19369 7.3499 8.35039 7.1932 8.35039 6.9999C8.35039 6.8066 8.19369 6.6499 8.00039 6.6499H2.00039Z"></path></svg>
		</button>

	</div></div>
		<nav aria-label="Main" class="ml-auto hidden lg:block"><ul class="flex items-center space-x-1.5 2xl:space-x-2"><li class="hover:text-indigo-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/models"><svg class="mr-1.5 text-gray-400 group-hover:text-indigo-500" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-quaternary" d="M20.23 7.24L12 12L3.77 7.24a1.98 1.98 0 0 1 .7-.71L11 2.76c.62-.35 1.38-.35 2 0l6.53 3.77c.29.173.531.418.7.71z" opacity=".25" fill="currentColor"></path><path class="uim-tertiary" d="M12 12v9.5a2.09 2.09 0 0 1-.91-.21L4.5 17.48a2.003 2.003 0 0 1-1-1.73v-7.5a2.06 2.06 0 0 1 .27-1.01L12 12z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M20.5 8.25v7.5a2.003 2.003 0 0 1-1 1.73l-6.62 3.82c-.275.13-.576.198-.88.2V12l8.23-4.76c.175.308.268.656.27 1.01z" fill="currentColor"></path></svg>
					Models</a>
			</li><li class="hover:text-red-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/datasets"><svg class="mr-1.5 text-gray-400 group-hover:text-red-500" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 25 25"><ellipse cx="12.5" cy="5" fill="currentColor" fill-opacity="0.25" rx="7.5" ry="2"></ellipse><path d="M12.5 15C16.6421 15 20 14.1046 20 13V20C20 21.1046 16.6421 22 12.5 22C8.35786 22 5 21.1046 5 20V13C5 14.1046 8.35786 15 12.5 15Z" fill="currentColor" opacity="0.5"></path><path d="M12.5 7C16.6421 7 20 6.10457 20 5V11.5C20 12.6046 16.6421 13.5 12.5 13.5C8.35786 13.5 5 12.6046 5 11.5V5C5 6.10457 8.35786 7 12.5 7Z" fill="currentColor" opacity="0.5"></path><path d="M5.23628 12C5.08204 12.1598 5 12.8273 5 13C5 14.1046 8.35786 15 12.5 15C16.6421 15 20 14.1046 20 13C20 12.8273 19.918 12.1598 19.7637 12C18.9311 12.8626 15.9947 13.5 12.5 13.5C9.0053 13.5 6.06886 12.8626 5.23628 12Z" fill="currentColor"></path></svg>
					Datasets</a>
			</li><li class="hover:text-blue-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/spaces"><svg class="mr-1.5 text-gray-400 group-hover:text-blue-500" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 25 25"><path opacity=".5" d="M6.016 14.674v4.31h4.31v-4.31h-4.31ZM14.674 14.674v4.31h4.31v-4.31h-4.31ZM6.016 6.016v4.31h4.31v-4.31h-4.31Z" fill="currentColor"></path><path opacity=".75" fill-rule="evenodd" clip-rule="evenodd" d="M3 4.914C3 3.857 3.857 3 4.914 3h6.514c.884 0 1.628.6 1.848 1.414a5.171 5.171 0 0 1 7.31 7.31c.815.22 1.414.964 1.414 1.848v6.514A1.914 1.914 0 0 1 20.086 22H4.914A1.914 1.914 0 0 1 3 20.086V4.914Zm3.016 1.102v4.31h4.31v-4.31h-4.31Zm0 12.968v-4.31h4.31v4.31h-4.31Zm8.658 0v-4.31h4.31v4.31h-4.31Zm0-10.813a2.155 2.155 0 1 1 4.31 0 2.155 2.155 0 0 1-4.31 0Z" fill="currentColor"></path><path opacity=".25" d="M16.829 6.016a2.155 2.155 0 1 0 0 4.31 2.155 2.155 0 0 0 0-4.31Z" fill="currentColor"></path></svg>
					Spaces</a>
			</li><li class="hover:text-yellow-700 max-xl:hidden"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/posts"><svg class="mr-1.5 text-gray-400 group-hover:text-yellow-500 text-yellow-500!" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 12 12" preserveAspectRatio="xMidYMid meet"><path fill="currentColor" fill-rule="evenodd" d="M3.73 2.4A4.25 4.25 0 1 1 6 10.26H2.17l-.13-.02a.43.43 0 0 1-.3-.43l.01-.06a.43.43 0 0 1 .12-.22l.84-.84A4.26 4.26 0 0 1 3.73 2.4Z" clip-rule="evenodd"></path></svg>
					Posts</a>
			</li><li class="hover:text-yellow-700"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/docs"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" class="mr-1.5 text-gray-400 group-hover:text-yellow-500" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 16 16"><path d="m2.28 3.7-.3.16a.67.67 0 0 0-.34.58v8.73l.01.04.02.07.01.04.03.06.02.04.02.03.04.06.05.05.04.04.06.04.06.04.08.04.08.02h.05l.07.02h.11l.04-.01.07-.02.03-.01.07-.03.22-.12a5.33 5.33 0 0 1 5.15.1.67.67 0 0 0 .66 0 5.33 5.33 0 0 1 5.33 0 .67.67 0 0 0 1-.58V4.36a.67.67 0 0 0-.34-.5l-.3-.17v7.78a.63.63 0 0 1-.87.59 4.9 4.9 0 0 0-4.35.35l-.65.39a.29.29 0 0 1-.15.04.29.29 0 0 1-.16-.04l-.65-.4a4.9 4.9 0 0 0-4.34-.34.63.63 0 0 1-.87-.59V3.7Z" fill="currentColor" class="dark:opacity-40"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M8 3.1a5.99 5.99 0 0 0-5.3-.43.66.66 0 0 0-.42.62v8.18c0 .45.46.76.87.59a4.9 4.9 0 0 1 4.34.35l.65.39c.05.03.1.04.16.04.05 0 .1-.01.15-.04l.65-.4a4.9 4.9 0 0 1 4.35-.34.63.63 0 0 0 .86-.59V3.3a.67.67 0 0 0-.41-.62 5.99 5.99 0 0 0-5.3.43l-.3.17L8 3.1Zm.73 1.87a.43.43 0 1 0-.86 0v5.48a.43.43 0 0 0 .86 0V4.97Z" fill="currentColor" class="opacity-40 dark:opacity-100"></path><path d="M8.73 4.97a.43.43 0 1 0-.86 0v5.48a.43.43 0 1 0 .86 0V4.96Z" fill="currentColor" class="dark:opacity-40"></path></svg>
					Docs</a>
			</li><li class="hover:text-black dark:hover:text-white"><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/enterprise"><svg class="mr-1.5 text-gray-400 group-hover:text-black dark:group-hover:text-white" xmlns="http://www.w3.org/2000/svg" fill="none" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 33 27"><path fill="currentColor" fill-rule="evenodd" d="M13.5.7a8.7 8.7 0 0 0-7.7 5.7L1 20.6c-1 3.1.9 5.7 4.1 5.7h15c3.3 0 6.8-2.6 7.8-5.7l4.6-14.2c1-3.1-.8-5.7-4-5.7h-15Zm1.1 5.7L9.8 20.3h9.8l1-3.1h-5.8l.8-2.5h4.8l1.1-3h-4.8l.8-2.3H23l1-3h-9.5Z" clip-rule="evenodd"></path></svg>
					Enterprise</a>
			</li>

		<li><a class="group flex items-center px-2 py-0.5 dark:text-gray-300 dark:hover:text-gray-100" href="/pricing">Pricing
			</a></li>

		<li><div class="relative group">
	<button class="px-2 py-0.5 hover:text-gray-500 dark:hover:text-gray-600 flex items-center " type="button">
		<svg class=" text-gray-500 w-5 group-hover:text-gray-400 dark:text-gray-300 dark:group-hover:text-gray-100" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 32 18" preserveAspectRatio="xMidYMid meet"><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 3.30221C14.4504 2.836 14.8284 2.45807 15.2946 2.45807H28.4933C28.9595 2.45807 29.3374 2.836 29.3374 3.30221C29.3374 3.76842 28.9595 4.14635 28.4933 4.14635H15.2946C14.8284 4.14635 14.4504 3.76842 14.4504 3.30221Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 9.00002C14.4504 8.53382 14.8284 8.15588 15.2946 8.15588H28.4933C28.9595 8.15588 29.3374 8.53382 29.3374 9.00002C29.3374 9.46623 28.9595 9.84417 28.4933 9.84417H15.2946C14.8284 9.84417 14.4504 9.46623 14.4504 9.00002Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M14.4504 14.6978C14.4504 14.2316 14.8284 13.8537 15.2946 13.8537H28.4933C28.9595 13.8537 29.3374 14.2316 29.3374 14.6978C29.3374 15.164 28.9595 15.542 28.4933 15.542H15.2946C14.8284 15.542 14.4504 15.164 14.4504 14.6978Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M1.94549 6.87377C2.27514 6.54411 2.80962 6.54411 3.13928 6.87377L6.23458 9.96907L9.32988 6.87377C9.65954 6.54411 10.194 6.54411 10.5237 6.87377C10.8533 7.20343 10.8533 7.73791 10.5237 8.06756L6.23458 12.3567L1.94549 8.06756C1.61583 7.73791 1.61583 7.20343 1.94549 6.87377Z" fill="currentColor"></path></svg>
			
		</button>
	
	
	</div></li>
		<li><hr class="h-5 w-0.5 border-none bg-gray-100 dark:bg-gray-800"></li>
		<li><a class="block cursor-pointer whitespace-nowrap px-2 py-0.5 hover:text-gray-500 dark:text-gray-300 dark:hover:text-gray-100" href="/login">Log In
				</a></li>
			<li><a class="whitespace-nowrap rounded-full border border-transparent bg-gray-900 px-3 py-1 leading-none text-white hover:border-black hover:bg-white hover:text-black" href="/join">Sign Up
					</a></li></ul></nav></div></header></div>
	
	
	
	<div class="SVELTE_HYDRATER contents" data-target="SSOBanner" data-props="{}"></div>
	
	

	<main class="flex flex-1 flex-col">
	<div class="SVELTE_HYDRATER contents" data-target="DatasetHeader" data-props="{&quot;activeTab&quot;:&quot;datasetCard&quot;,&quot;author&quot;:{&quot;_id&quot;:&quot;649dcd0847f0b95dd28f6008&quot;,&quot;avatarUrl&quot;:&quot;/avatars/681b1b84bb633fef11604c5c09c07841.svg&quot;,&quot;fullname&quot;:&quot;jay deyoung&quot;,&quot;name&quot;:&quot;jaydeyoung&quot;,&quot;type&quot;:&quot;user&quot;,&quot;isPro&quot;:false,&quot;isHf&quot;:false,&quot;isHfAdmin&quot;:false,&quot;isMod&quot;:false},&quot;canReadRepoSettings&quot;:false,&quot;dataset&quot;:{&quot;author&quot;:&quot;jaydeyoung&quot;,&quot;cardData&quot;:{&quot;pretty_name&quot;:&quot;Evidence Infer Treatment&quot;,&quot;annotations_creators&quot;:[&quot;expert-generated&quot;],&quot;language_creators&quot;:[&quot;expert-generated&quot;],&quot;language&quot;:[&quot;en&quot;],&quot;license&quot;:[&quot;mit&quot;],&quot;multilinguality&quot;:[&quot;monolingual&quot;],&quot;size_categories&quot;:[&quot;1K<n<10K&quot;],&quot;source_datasets&quot;:[&quot;original&quot;],&quot;task_categories&quot;:[&quot;text-retrieval&quot;],&quot;task_ids&quot;:[&quot;fact-checking-retrieval&quot;],&quot;paperswithcode_id&quot;:null,&quot;dataset_info&quot;:[{&quot;config_name&quot;:&quot;2.0&quot;,&quot;features&quot;:[{&quot;name&quot;:&quot;Text&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Prompts&quot;,&quot;sequence&quot;:[{&quot;name&quot;:&quot;PromptID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Outcome&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Intervention&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Comparator&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Annotations&quot;,&quot;sequence&quot;:[{&quot;name&quot;:&quot;UserID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PromptID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Valid Label&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Valid Reasoning&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Label&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Annotations&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Label Code&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;In Abstract&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Evidence Start&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Evidence End&quot;,&quot;dtype&quot;:&quot;int32&quot;}]}]}],&quot;splits&quot;:[{&quot;name&quot;:&quot;train&quot;,&quot;num_bytes&quot;:77045294,&quot;num_examples&quot;:2690},{&quot;name&quot;:&quot;test&quot;,&quot;num_bytes&quot;:9436674,&quot;num_examples&quot;:334},{&quot;name&quot;:&quot;validation&quot;,&quot;num_bytes&quot;:10113982,&quot;num_examples&quot;:340}],&quot;download_size&quot;:163515689,&quot;dataset_size&quot;:96595950},{&quot;config_name&quot;:&quot;1.1&quot;,&quot;features&quot;:[{&quot;name&quot;:&quot;Text&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Prompts&quot;,&quot;sequence&quot;:[{&quot;name&quot;:&quot;PromptID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Outcome&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Intervention&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Comparator&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Annotations&quot;,&quot;sequence&quot;:[{&quot;name&quot;:&quot;UserID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PromptID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;PMCID&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Valid Label&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Valid Reasoning&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Label&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Annotations&quot;,&quot;dtype&quot;:&quot;string&quot;},{&quot;name&quot;:&quot;Label Code&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;In Abstract&quot;,&quot;dtype&quot;:&quot;bool&quot;},{&quot;name&quot;:&quot;Evidence Start&quot;,&quot;dtype&quot;:&quot;int32&quot;},{&quot;name&quot;:&quot;Evidence End&quot;,&quot;dtype&quot;:&quot;int32&quot;}]}]}],&quot;splits&quot;:[{&quot;name&quot;:&quot;train&quot;,&quot;num_bytes&quot;:55375971,&quot;num_examples&quot;:1931},{&quot;name&quot;:&quot;test&quot;,&quot;num_bytes&quot;:6877338,&quot;num_examples&quot;:240},{&quot;name&quot;:&quot;validation&quot;,&quot;num_bytes&quot;:7359847,&quot;num_examples&quot;:248}],&quot;download_size&quot;:114452688,&quot;dataset_size&quot;:69613156}]},&quot;cardExists&quot;:true,&quot;createdAt&quot;:&quot;2022-03-02T23:29:22.000Z&quot;,&quot;citation&quot;:&quot;@inproceedings{lehman-etal-2019-inferring,\n    title = \&quot;Inferring Which Medical Treatments Work from Reports of Clinical Trials\&quot;,\n    author = \&quot;Lehman, Eric  and\n      DeYoung, Jay  and\n      Barzilay, Regina  and\n      Wallace, Byron C.\&quot;,\n    booktitle = \&quot;Proceedings of the 2019 Conference of the North {A}merican Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers)\&quot;,\n    month = jun,\n    year = \&quot;2019\&quot;,\n    address = \&quot;Minneapolis, Minnesota\&quot;,\n    publisher = \&quot;Association for Computational Linguistics\&quot;,\n    url = \&quot;https://www.aclweb.org/anthology/N19-1371\&quot;,\n    pages = \&quot;3705--3717\&quot;,\n}&quot;,&quot;description&quot;:&quot;Data and code from our \&quot;Inferring Which Medical Treatments Work from Reports of Clinical Trials\&quot;, NAACL 2019. This work concerns inferring the results reported in clinical trials from text.\n\nThe dataset consists of biomedical articles describing randomized control trials (RCTs) that compare multiple treatments. Each of these articles will have multiple questions, or 'prompts' associated with them. These prompts will ask about the relationship between an intervention and comparator with respect to an outcome, as reported in the trial. For example, a prompt may ask about the reported effects of aspirin as compared to placebo on the duration of headaches. For the sake of this task, we assume that a particular article will report that the intervention of interest either significantly increased, significantly decreased or had significant effect on the outcome, relative to the comparator.\n\nThe dataset could be used for automatic data extraction of the results of a given RCT. This would enable readers to discover the effectiveness of different treatments without needing to read the paper.&quot;,&quot;downloads&quot;:183,&quot;downloadsAllTime&quot;:125156,&quot;id&quot;:&quot;jaydeyoung/evidence_infer_treatment&quot;,&quot;isLikedByUser&quot;:false,&quot;lastModified&quot;:&quot;2024-01-18T11:03:29.000Z&quot;,&quot;likes&quot;:7,&quot;discussionsDisabled&quot;:false,&quot;repoType&quot;:&quot;dataset&quot;,&quot;private&quot;:false,&quot;gated&quot;:false,&quot;tags&quot;:[&quot;task_categories:text-retrieval&quot;,&quot;task_ids:fact-checking-retrieval&quot;,&quot;annotations_creators:expert-generated&quot;,&quot;language_creators:expert-generated&quot;,&quot;multilinguality:monolingual&quot;,&quot;source_datasets:original&quot;,&quot;language:en&quot;,&quot;license:mit&quot;,&quot;size_categories:1K<n<10K&quot;,&quot;arxiv:2005.04177&quot;,&quot;region:us&quot;],&quot;tag_objs&quot;:[{&quot;id&quot;:&quot;task_categories:text-retrieval&quot;,&quot;label&quot;:&quot;text-retrieval&quot;,&quot;type&quot;:&quot;task_categories&quot;,&quot;subType&quot;:&quot;nlp&quot;},{&quot;id&quot;:&quot;task_ids:fact-checking-retrieval&quot;,&quot;label&quot;:&quot;fact-checking-retrieval&quot;,&quot;type&quot;:&quot;task_ids&quot;},{&quot;id&quot;:&quot;annotations_creators:expert-generated&quot;,&quot;label&quot;:&quot;expert-generated&quot;,&quot;type&quot;:&quot;annotations_creators&quot;},{&quot;id&quot;:&quot;language_creators:expert-generated&quot;,&quot;label&quot;:&quot;expert-generated&quot;,&quot;type&quot;:&quot;language_creators&quot;},{&quot;id&quot;:&quot;multilinguality:monolingual&quot;,&quot;label&quot;:&quot;monolingual&quot;,&quot;type&quot;:&quot;multilinguality&quot;},{&quot;id&quot;:&quot;source_datasets:original&quot;,&quot;label&quot;:&quot;original&quot;,&quot;type&quot;:&quot;source_datasets&quot;},{&quot;id&quot;:&quot;language:en&quot;,&quot;label&quot;:&quot;English&quot;,&quot;type&quot;:&quot;language&quot;},{&quot;id&quot;:&quot;license:mit&quot;,&quot;label&quot;:&quot;mit&quot;,&quot;type&quot;:&quot;license&quot;},{&quot;id&quot;:&quot;size_categories:1K<n<10K&quot;,&quot;label&quot;:&quot;1K<n<10K&quot;,&quot;type&quot;:&quot;size_categories&quot;},{&quot;id&quot;:&quot;arxiv:2005.04177&quot;,&quot;label&quot;:&quot;arxiv:2005.04177&quot;,&quot;type&quot;:&quot;arxiv&quot;,&quot;extra&quot;:{&quot;paperTitle&quot;:&quot;Evidence Inference 2.0: More Data, Better Models&quot;}},{&quot;type&quot;:&quot;region&quot;,&quot;label&quot;:&quot;ðŸ‡ºðŸ‡¸ Region: US&quot;,&quot;id&quot;:&quot;region:us&quot;}],&quot;homepage&quot;:&quot;http://evidence-inference.ebm-nlp.com/&quot;,&quot;hasBlockedOids&quot;:false,&quot;region&quot;:&quot;us&quot;,&quot;xetEnabled&quot;:false},&quot;discussionsStats&quot;:{&quot;closed&quot;:3,&quot;open&quot;:0,&quot;total&quot;:3}}"><header class="bg-linear-to-t border-b border-gray-100 pt-6 sm:pt-9 from-gray-50-to-white via-white dark:via-gray-950"><div class="container relative "><h1 class="flex flex-wrap items-center max-md:leading-tight mb-3 text-lg max-sm:gap-y-1.5 md:text-xl"><a href="/datasets" class="group flex items-center"><svg class="sm:mr-1.5 -mr-1 text-gray-400" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 25 25"><ellipse cx="12.5" cy="5" fill="currentColor" fill-opacity="0.25" rx="7.5" ry="2"></ellipse><path d="M12.5 15C16.6421 15 20 14.1046 20 13V20C20 21.1046 16.6421 22 12.5 22C8.35786 22 5 21.1046 5 20V13C5 14.1046 8.35786 15 12.5 15Z" fill="currentColor" opacity="0.5"></path><path d="M12.5 7C16.6421 7 20 6.10457 20 5V11.5C20 12.6046 16.6421 13.5 12.5 13.5C8.35786 13.5 5 12.6046 5 11.5V5C5 6.10457 8.35786 7 12.5 7Z" fill="currentColor" opacity="0.5"></path><path d="M5.23628 12C5.08204 12.1598 5 12.8273 5 13C5 14.1046 8.35786 15 12.5 15C16.6421 15 20 14.1046 20 13C20 12.8273 19.918 12.1598 19.7637 12C18.9311 12.8626 15.9947 13.5 12.5 13.5C9.0053 13.5 6.06886 12.8626 5.23628 12Z" fill="currentColor"></path></svg>
					<span class="mr-2.5 font-semibold text-gray-400 group-hover:text-gray-500 max-sm:hidden">Datasets:</span></a>
				<hr class="mx-1.5 h-2 translate-y-px rounded-sm border-r dark:border-gray-600 sm:hidden">
			<div class="group flex flex-none items-center"><div class="relative mr-1 flex items-center">

			

<span class="inline-block "><span class="contents"><a href="/jaydeyoung" class="text-gray-400 hover:text-blue-600"><img alt="" class="w-3.5 h-3.5 rounded-full  flex-none" src="/avatars/681b1b84bb633fef11604c5c09c07841.svg" crossorigin="anonymous"></a></span>
	</span></div>
		

<span class="inline-block "><span class="contents"><a href="/jaydeyoung" class="text-gray-400 hover:text-blue-600">jaydeyoung</a></span>
	</span>
		<div class="mx-0.5 text-gray-300">/</div></div>

<div class="max-w-full "><a class="break-words font-mono font-semibold hover:text-blue-600 " href="/datasets/jaydeyoung/evidence_infer_treatment">evidence_infer_treatment</a>
	<button class="relative text-sm mr-4 focus:outline-hidden inline-flex cursor-pointer items-center text-sm  mx-0.5   text-gray-600 " title="Copy dataset name to clipboard" type="button"><svg class="" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M28,10V28H10V10H28m0-2H10a2,2,0,0,0-2,2V28a2,2,0,0,0,2,2H28a2,2,0,0,0,2-2V10a2,2,0,0,0-2-2Z" transform="translate(0)"></path><path d="M4,18H2V4A2,2,0,0,1,4,2H18V4H4Z" transform="translate(0)"></path><rect fill="none" width="32" height="32"></rect></svg>
	
	</button></div>
			<div class="inline-flex items-center overflow-hidden whitespace-nowrap rounded-md border bg-white text-sm leading-none text-gray-500  mr-2"><button class="relative flex items-center overflow-hidden from-red-50 to-transparent dark:from-red-900 px-1.5 py-1 hover:bg-linear-to-t focus:outline-hidden"  title="Like"><svg class="left-1.5 absolute" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32" fill="currentColor"><path d="M22.45,6a5.47,5.47,0,0,1,3.91,1.64,5.7,5.7,0,0,1,0,8L16,26.13,5.64,15.64a5.7,5.7,0,0,1,0-8,5.48,5.48,0,0,1,7.82,0L16,10.24l2.53-2.58A5.44,5.44,0,0,1,22.45,6m0-2a7.47,7.47,0,0,0-5.34,2.24L16,7.36,14.89,6.24a7.49,7.49,0,0,0-10.68,0,7.72,7.72,0,0,0,0,10.82L16,29,27.79,17.06a7.72,7.72,0,0,0,0-10.82A7.49,7.49,0,0,0,22.45,4Z"></path></svg>

		
		<span class="ml-4 pl-0.5 ">like</span></button>
	<button class="focus:outline-hidden flex items-center border-l px-1.5 py-1 text-gray-400 hover:bg-gray-50 focus:bg-gray-100 dark:hover:bg-gray-900 dark:focus:bg-gray-800" title="See users who liked this repository">7</button></div>




			
			
	</h1>
		<div class="mb-3 flex flex-wrap md:mb-4"><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Tasks:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?task_categories=task_categories%3Atext-retrieval"><div class="tag tag-white   "><div class="tag-ico -ml-2 tag-ico-indigo"><svg class="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 18 19"><path d="M12.3625 13.85H10.1875V12.7625H12.3625V10.5875H13.45V12.7625C13.4497 13.0508 13.335 13.3272 13.1312 13.5311C12.9273 13.735 12.6508 13.8497 12.3625 13.85V13.85Z"></path><path d="M5.8375 8.41246H4.75V6.23746C4.75029 5.94913 4.86496 5.67269 5.06884 5.4688C5.27272 5.26492 5.54917 5.15025 5.8375 5.14996H8.0125V6.23746H5.8375V8.41246Z"></path><path d="M15.625 5.14998H13.45V2.97498C13.4497 2.68665 13.335 2.4102 13.1312 2.20632C12.9273 2.00244 12.6508 1.88777 12.3625 1.88748H2.575C2.28666 1.88777 2.01022 2.00244 1.80633 2.20632C1.60245 2.4102 1.48778 2.68665 1.4875 2.97498V12.7625C1.48778 13.0508 1.60245 13.3273 1.80633 13.5311C2.01022 13.735 2.28666 13.8497 2.575 13.85H4.75V16.025C4.75028 16.3133 4.86495 16.5898 5.06883 16.7936C5.27272 16.9975 5.54916 17.1122 5.8375 17.1125H15.625C15.9133 17.1122 16.1898 16.9975 16.3937 16.7936C16.5975 16.5898 16.7122 16.3133 16.7125 16.025V6.23748C16.7122 5.94915 16.5975 5.6727 16.3937 5.46882C16.1898 5.26494 15.9133 5.15027 15.625 5.14998V5.14998ZM15.625 16.025H5.8375V13.85H8.0125V12.7625H5.8375V10.5875H4.75V12.7625H2.575V2.97498H12.3625V5.14998H10.1875V6.23748H12.3625V8.41248H13.45V6.23748H15.625V16.025Z"></path></svg></div>

	

	<span>Text Retrieval</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Sub-tasks:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?task_ids=task_ids%3Afact-checking-retrieval"><div class="tag tag-white   ">

	

	<span>fact-checking-retrieval</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Languages:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?language=language%3Aen"><div class="tag tag-white   ">
		<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" class="text-green-600/80" preserveAspectRatio="xMidYMid meet" width="1em" height="1em" viewBox="0 0 10 10"><path fill-rule="evenodd" clip-rule="evenodd" d="M0.625 5C0.625 6.16032 1.08594 7.27312 1.90641 8.09359C2.72688 8.91406 3.83968 9.375 5 9.375C6.16032 9.375 7.27312 8.91406 8.09359 8.09359C8.91406 7.27312 9.375 6.16032 9.375 5C9.375 3.83968 8.91406 2.72688 8.09359 1.90641C7.27312 1.08594 6.16032 0.625 5 0.625C3.83968 0.625 2.72688 1.08594 1.90641 1.90641C1.08594 2.72688 0.625 3.83968 0.625 5ZM7.64365 7.48027C7.61734 7.50832 7.59054 7.53598 7.56326 7.56326C7.13828 7.98824 6.61864 8.2968 6.0539 8.46842C6.29802 8.11949 6.49498 7.64804 6.63475 7.09483C7.00845 7.18834 7.35014 7.3187 7.64365 7.48027ZM8.10076 6.87776C8.37677 6.42196 8.55005 5.90894 8.60556 5.37499H6.86808C6.85542 5.71597 6.82551 6.04557 6.77971 6.35841C7.25309 6.47355 7.68808 6.6414 8.062 6.85549C8.07497 6.86283 8.08789 6.87025 8.10076 6.87776ZM6.03795 6.22536C6.07708 5.95737 6.1044 5.67232 6.11705 5.37499H3.88295C3.89666 5.69742 3.92764 6.00542 3.9722 6.29287C4.37075 6.21726 4.79213 6.17749 5.224 6.17749C5.50054 6.17749 5.77294 6.19376 6.03795 6.22536ZM4.1261 7.02673C4.34894 7.84835 4.68681 8.375 5 8.375C5.32122 8.375 5.66839 7.82101 5.8908 6.963C5.67389 6.93928 5.45082 6.92699 5.224 6.92699C4.84316 6.92699 4.47332 6.96176 4.1261 7.02673ZM3.39783 7.21853C3.53498 7.71842 3.72038 8.14579 3.9461 8.46842C3.42141 8.30898 2.93566 8.03132 2.52857 7.65192C2.77253 7.48017 3.06711 7.33382 3.39783 7.21853ZM3.23916 6.48077C3.18263 6.13193 3.14625 5.76074 3.13192 5.37499H1.39444C1.4585 5.99112 1.67936 6.57938 2.03393 7.08403C2.3706 6.83531 2.78055 6.63162 3.23916 6.48077ZM1.39444 4.62499H3.13192C3.14615 4.24204 3.18211 3.87344 3.23794 3.52681C2.77814 3.37545 2.36731 3.17096 2.03024 2.92123C1.67783 3.42469 1.45828 4.011 1.39444 4.62499ZM2.5237 2.35262C2.76812 2.52552 3.06373 2.67281 3.39584 2.78875C3.53318 2.28573 3.71928 1.85578 3.9461 1.53158C3.41932 1.69166 2.93178 1.97089 2.5237 2.35262ZM3.97101 3.71489C3.92709 4.00012 3.89654 4.30547 3.88295 4.62499H6.11705C6.10453 4.33057 6.07761 4.04818 6.03909 3.78248C5.77372 3.81417 5.50093 3.83049 5.224 3.83049C4.79169 3.83049 4.3699 3.79065 3.97101 3.71489ZM5.8928 3.04476C5.67527 3.06863 5.45151 3.08099 5.224 3.08099C4.84241 3.08099 4.47186 3.04609 4.12405 2.98086C4.34686 2.1549 4.68584 1.625 5 1.625C5.32218 1.625 5.67048 2.18233 5.8928 3.04476ZM6.78083 3.6493C6.826 3.95984 6.85552 4.28682 6.86808 4.62499H8.60556C8.55029 4.09337 8.37827 3.58251 8.10436 3.1282C8.0903 3.1364 8.07618 3.14449 8.062 3.15249C7.68838 3.36641 7.25378 3.53417 6.78083 3.6493ZM7.64858 2.52499C7.35446 2.68754 7.0117 2.81868 6.63664 2.91268C6.49676 2.35623 6.29913 1.88209 6.0539 1.53158C6.61864 1.7032 7.13828 2.01176 7.56326 2.43674C7.59224 2.46572 7.62068 2.49514 7.64858 2.52499Z" fill="currentColor"></path></svg>

	

	<span>English</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">Size:
	</span>
	<a class="mb-1 mr-1 md:mb-1.5 md:mr-1.5 rounded-lg" href="/datasets?size_categories=size_categories%3A1K%3Cn%3C10K"><div class="tag tag-white   ">

	

	<span>1K&lt;n&lt;10K</span>
	

	</div></a>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">ArXiv:
	</span>
	

	<div class="relative inline-block ">
	<button class="group mr-1 mb-1 md:mr-1.5 md:mb-1.5  rounded-full rounded-br-none " type="button">
		<div class="tag tag-white rounded-full  relative rounded-br-none pr-2.5">
		<svg class="-mr-1 text-gray-400" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" viewBox="0 0 12 12" preserveAspectRatio="xMidYMid meet" fill="none"><path fill="currentColor" fill-rule="evenodd" d="M8.007 1.814a1.176 1.176 0 0 0-.732-.266H3.088c-.64 0-1.153.512-1.153 1.152v6.803c0 .64.513 1.152 1.153 1.152h5.54c.632 0 1.144-.511 1.144-1.152V3.816c0-.338-.137-.658-.412-.887L8.007 1.814Zm-1.875 1.81c0 .695.55 1.253 1.244 1.253h.983a.567.567 0 0 1 .553.585v4.041c0 .165-.119.302-.283.302h-5.55c-.156 0-.275-.137-.275-.302V2.7a.284.284 0 0 1 .284-.301h2.468a.574.574 0 0 1 .434.19.567.567 0 0 1 .142.395v.64Z" clip-rule="evenodd"></path><path fill="currentColor" fill-opacity=".2" fill-rule="evenodd" d="M6.132 3.624c0 .695.55 1.253 1.244 1.253h.97a.567.567 0 0 1 .566.585v4.041c0 .165-.119.302-.283.302h-5.55c-.156 0-.275-.137-.275-.302V2.7a.284.284 0 0 1 .284-.301h2.468a.567.567 0 0 1 .576.585v.64Z" clip-rule="evenodd"></path></svg>

	

	<span class="-mr-2 text-gray-400">arxiv:</span>
		<span>2005.04177</span>
	

	<div class="border-br-gray-200 absolute bottom-0.5 right-0.5 h-1 w-1 border-[3px] border-l-transparent border-t-transparent border-b-gray-200 border-r-gray-200 dark:border-b-gray-700 dark:border-r-gray-700"></div></div>
		
		</button>
	
	
	</div>

	</div><div class="mr-1 flex flex-wrap items-center"><span class="mb-1 mr-1 p-1 text-sm leading-tight text-gray-400 md:mb-1.5">License:
	</span>
	<div class="relative inline-block ">
	<button class="group mr-1 mb-1 md:mr-1.5 md:mb-1.5  rounded-full rounded-br-none " type="button">
		<div class="tag tag-white rounded-full  relative rounded-br-none pr-2.5">
		<svg class="text-xs text-gray-900" width="1em" height="1em" viewBox="0 0 10 10" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M1.46009 5.0945V6.88125C1.46009 7.25201 1.75937 7.55129 2.13012 7.55129C2.50087 7.55129 2.80016 7.25201 2.80016 6.88125V5.0945C2.80016 4.72375 2.50087 4.42446 2.13012 4.42446C1.75937 4.42446 1.46009 4.72375 1.46009 5.0945ZM4.14022 5.0945V6.88125C4.14022 7.25201 4.4395 7.55129 4.81026 7.55129C5.18101 7.55129 5.48029 7.25201 5.48029 6.88125V5.0945C5.48029 4.72375 5.18101 4.42446 4.81026 4.42446C4.4395 4.42446 4.14022 4.72375 4.14022 5.0945ZM1.23674 9.78473H8.38377C8.75452 9.78473 9.0538 9.48545 9.0538 9.1147C9.0538 8.74395 8.75452 8.44466 8.38377 8.44466H1.23674C0.865993 8.44466 0.566711 8.74395 0.566711 9.1147C0.566711 9.48545 0.865993 9.78473 1.23674 9.78473ZM6.82036 5.0945V6.88125C6.82036 7.25201 7.11964 7.55129 7.49039 7.55129C7.86114 7.55129 8.16042 7.25201 8.16042 6.88125V5.0945C8.16042 4.72375 7.86114 4.42446 7.49039 4.42446C7.11964 4.42446 6.82036 4.72375 6.82036 5.0945ZM4.39484 0.623142L0.865993 2.48137C0.682851 2.57517 0.566711 2.76725 0.566711 2.97273C0.566711 3.28094 0.816857 3.53109 1.12507 3.53109H8.49991C8.80365 3.53109 9.0538 3.28094 9.0538 2.97273C9.0538 2.76725 8.93766 2.57517 8.75452 2.48137L5.22568 0.623142C4.9666 0.484669 4.65391 0.484669 4.39484 0.623142V0.623142Z" fill="currentColor"></path></svg>

	

	<span>mit</span>
	

	<div class="border-br-gray-200 absolute bottom-0.5 right-0.5 h-1 w-1 border-[3px] border-l-transparent border-t-transparent border-b-gray-200 border-r-gray-200 dark:border-b-gray-700 dark:border-r-gray-700"></div></div>
		
		</button>
	
	
	</div>

	</div></div>

		<div class="flex flex-col-reverse lg:flex-row lg:items-center lg:justify-between"><div class="-mb-px flex h-12 items-center overflow-x-auto overflow-y-hidden ">
	<a class="tab-alternate active" href="/datasets/jaydeyoung/evidence_infer_treatment"><svg class="mr-1.5 text-gray-400 flex-none" style="" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-quaternary" d="M20.23 7.24L12 12L3.77 7.24a1.98 1.98 0 0 1 .7-.71L11 2.76c.62-.35 1.38-.35 2 0l6.53 3.77c.29.173.531.418.7.71z" opacity=".25" fill="currentColor"></path><path class="uim-tertiary" d="M12 12v9.5a2.09 2.09 0 0 1-.91-.21L4.5 17.48a2.003 2.003 0 0 1-1-1.73v-7.5a2.06 2.06 0 0 1 .27-1.01L12 12z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M20.5 8.25v7.5a2.003 2.003 0 0 1-1 1.73l-6.62 3.82c-.275.13-.576.198-.88.2V12l8.23-4.76c.175.308.268.656.27 1.01z" fill="currentColor"></path></svg>
	Dataset card
	

	
		</a><a class="tab-alternate" href="/datasets/jaydeyoung/evidence_infer_treatment/tree/main"><svg class="mr-1.5 text-gray-400 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 24 24"><path class="uim-tertiary" d="M21 19h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0-4h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0-8h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2zm0 4h-8a1 1 0 0 1 0-2h8a1 1 0 0 1 0 2z" opacity=".5" fill="currentColor"></path><path class="uim-primary" d="M9 19a1 1 0 0 1-1-1V6a1 1 0 0 1 2 0v12a1 1 0 0 1-1 1zm-6-4.333a1 1 0 0 1-.64-1.769L3.438 12l-1.078-.898a1 1 0 0 1 1.28-1.538l2 1.667a1 1 0 0 1 0 1.538l-2 1.667a.999.999 0 0 1-.64.231z" fill="currentColor"></path></svg>
	<span class="xl:hidden">Files</span>
		<span class="hidden xl:inline">Files and versions</span>
	

	
		</a><a class="tab-alternate" href="/datasets/jaydeyoung/evidence_infer_treatment/discussions"><svg class="mr-1.5 text-gray-400 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M20.6081 3C21.7684 3 22.8053 3.49196 23.5284 4.38415C23.9756 4.93678 24.4428 5.82749 24.4808 7.16133C24.9674 7.01707 25.4353 6.93643 25.8725 6.93643C26.9833 6.93643 27.9865 7.37587 28.696 8.17411C29.6075 9.19872 30.0124 10.4579 29.8361 11.7177C29.7523 12.3177 29.5581 12.8555 29.2678 13.3534C29.8798 13.8646 30.3306 14.5763 30.5485 15.4322C30.719 16.1032 30.8939 17.5006 29.9808 18.9403C30.0389 19.0342 30.0934 19.1319 30.1442 19.2318C30.6932 20.3074 30.7283 21.5229 30.2439 22.6548C29.5093 24.3704 27.6841 25.7219 24.1397 27.1727C21.9347 28.0753 19.9174 28.6523 19.8994 28.6575C16.9842 29.4379 14.3477 29.8345 12.0653 29.8345C7.87017 29.8345 4.8668 28.508 3.13831 25.8921C0.356375 21.6797 0.754104 17.8269 4.35369 14.1131C6.34591 12.058 7.67023 9.02782 7.94613 8.36275C8.50224 6.39343 9.97271 4.20438 12.4172 4.20438H12.4179C12.6236 4.20438 12.8314 4.2214 13.0364 4.25468C14.107 4.42854 15.0428 5.06476 15.7115 6.02205C16.4331 5.09583 17.134 4.359 17.7682 3.94323C18.7242 3.31737 19.6794 3 20.6081 3ZM20.6081 5.95917C20.2427 5.95917 19.7963 6.1197 19.3039 6.44225C17.7754 7.44319 14.8258 12.6772 13.7458 14.7131C13.3839 15.3952 12.7655 15.6837 12.2086 15.6837C11.1036 15.6837 10.2408 14.5497 12.1076 13.1085C14.9146 10.9402 13.9299 7.39584 12.5898 7.1776C12.5311 7.16799 12.4731 7.16355 12.4172 7.16355C11.1989 7.16355 10.6615 9.33114 10.6615 9.33114C10.6615 9.33114 9.0863 13.4148 6.38031 16.206C3.67434 18.998 3.5346 21.2388 5.50675 24.2246C6.85185 26.2606 9.42666 26.8753 12.0653 26.8753C14.8021 26.8753 17.6077 26.2139 19.1799 25.793C19.2574 25.7723 28.8193 22.984 27.6081 20.6107C27.4046 20.212 27.0693 20.0522 26.6471 20.0522C24.9416 20.0522 21.8393 22.6726 20.5057 22.6726C20.2076 22.6726 19.9976 22.5416 19.9116 22.222C19.3433 20.1173 28.552 19.2325 27.7758 16.1839C27.639 15.6445 27.2677 15.4256 26.746 15.4263C24.4923 15.4263 19.4358 19.5181 18.3759 19.5181C18.2949 19.5181 18.2368 19.4937 18.2053 19.4419C17.6743 18.557 17.9653 17.9394 21.7082 15.6009C25.4511 13.2617 28.0783 11.8545 26.5841 10.1752C26.4121 9.98141 26.1684 9.8956 25.8725 9.8956C23.6001 9.89634 18.2311 14.9403 18.2311 14.9403C18.2311 14.9403 16.7821 16.496 15.9057 16.496C15.7043 16.496 15.533 16.4139 15.4169 16.2112C14.7956 15.1296 21.1879 10.1286 21.5484 8.06535C21.7928 6.66715 21.3771 5.95917 20.6081 5.95917Z" fill="#FF9D00"></path><path d="M5.50686 24.2246C3.53472 21.2387 3.67446 18.9979 6.38043 16.206C9.08641 13.4147 10.6615 9.33111 10.6615 9.33111C10.6615 9.33111 11.2499 6.95933 12.59 7.17757C13.93 7.39581 14.9139 10.9401 12.1069 13.1084C9.29997 15.276 12.6659 16.7489 13.7459 14.713C14.8258 12.6772 17.7747 7.44316 19.304 6.44221C20.8326 5.44128 21.9089 6.00204 21.5484 8.06532C21.188 10.1286 14.795 15.1295 15.4171 16.2118C16.0391 17.2934 18.2312 14.9402 18.2312 14.9402C18.2312 14.9402 25.0907 8.49588 26.5842 10.1752C28.0776 11.8545 25.4512 13.2616 21.7082 15.6008C17.9646 17.9393 17.6744 18.557 18.2054 19.4418C18.7372 20.3266 26.9998 13.1351 27.7759 16.1838C28.5513 19.2324 19.3434 20.1173 19.9117 22.2219C20.48 24.3274 26.3979 18.2382 27.6082 20.6107C28.8193 22.9839 19.2574 25.7722 19.18 25.7929C16.0914 26.62 8.24723 28.3726 5.50686 24.2246Z" fill="#FFD21E"></path></svg>
	Community
	<div class="ml-1.5 flex h-4 min-w-[1rem] items-center justify-center rounded px-1 text-xs leading-none shadow-sm bg-gray-200 text-gray-600 dark:bg-gray-900 dark:text-gray-500">3</div>

	
		</a></div>
	
			</div></div></header>
</div>
	
<div class="container relative flex flex-col md:grid md:space-y-0 w-full md:grid-cols-12 md:flex-1 md:grid-rows-full space-y-4 md:gap-6 ">
		<section class="pt-6 border-gray-100 md:col-span-8 pb-24 relative break-words copiable-code-container">
				<div class="SVELTE_HYDRATER contents" data-target="UnsafeBanner" data-props="{&quot;classNames&quot;:&quot;mb-4&quot;,&quot;repoId&quot;:&quot;jaydeyoung/evidence_infer_treatment&quot;,&quot;repoType&quot;:&quot;dataset&quot;,&quot;minLevel&quot;:&quot;unsafe&quot;}"></div>
					<div class="SVELTE_HYDRATER contents" data-target="DatasetViewer" data-props="{&quot;data&quot;:{&quot;kind&quot;:&quot;ConfigError&quot;,&quot;error&quot;:{&quot;error&quot;:&quot;The dataset viewer doesn't support this dataset because it runs arbitrary Python code. You can convert it to a Parquet data-only dataset by using the convert_to_parquet CLI from the datasets library. See: https://huggingface.co/docs/datasets/main/en/cli#convert-to-parquet&quot;,&quot;error_code&quot;:&quot;DatasetWithScriptNotSupportedError&quot;},&quot;partial&quot;:false,&quot;jwt&quot;:&quot;eyJhbGciOiJFZERTQSJ9.eyJyZWFkIjp0cnVlLCJwZXJtaXNzaW9ucyI6eyJyZXBvLmNvbnRlbnQucmVhZCI6dHJ1ZX0sImlhdCI6MTc0MjkxODkwOCwic3ViIjoiL2RhdGFzZXRzL2pheWRleW91bmcvZXZpZGVuY2VfaW5mZXJfdHJlYXRtZW50IiwiZXhwIjoxNzQyOTIyNTA4LCJpc3MiOiJodHRwczovL2h1Z2dpbmdmYWNlLmNvIn0.buqevRBWW2BtXE-Ss6VasZn6rLw4Zq0oyvuWgzcSU5Nn9QPN0jXEqO4-YzChgA-mora8dqYnYxHwt9G9LLkaDA&quot;},&quot;dataset&quot;:&quot;jaydeyoung/evidence_infer_treatment&quot;,&quot;isGated&quot;:false,&quot;isPrivate&quot;:false,&quot;hasParquetFormat&quot;:false,&quot;author&quot;:{&quot;_id&quot;:&quot;649dcd0847f0b95dd28f6008&quot;,&quot;avatarUrl&quot;:&quot;/avatars/681b1b84bb633fef11604c5c09c07841.svg&quot;,&quot;fullname&quot;:&quot;jay deyoung&quot;,&quot;name&quot;:&quot;jaydeyoung&quot;,&quot;type&quot;:&quot;user&quot;,&quot;isPro&quot;:false,&quot;isHf&quot;:false,&quot;isHfAdmin&quot;:false,&quot;isMod&quot;:false},&quot;compact&quot;:true}"><div class="flex flex-col overflow-hidden shadow-xs mx-auto mb-10 rounded-lg border pt-2  px-2.5"><div class="mb-2 flex flex-wrap items-center gap-2"><div class="mr-auto flex items-center"><svg class="mr-1 flex-none" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 12 12"><path fill="currentColor" d="M2.5 2h7a1 1 0 0 1 1 1v6a1 1 0 0 1-1 1h-7a1 1 0 0 1-1-1V3a1 1 0 0 1 1-1Zm0 2v2h3V4h-3Zm4 0v2h3V4h-3Zm-4 3v2h3V7h-3Zm4 0v2h3V7h-3Z"></path></svg>
	<div class="whitespace-nowrap font-semibold">Dataset Viewer</div>
	</div>
				
				</div>
		<div class=" py-1 font-mono text-xs text-gray-600"><p class="mb-2">The viewer is disabled because this dataset repo requires arbitrary Python code execution. Please consider
			removing the
			<a class="underline" href="https://huggingface.co/docs/datasets/dataset_script">loading script</a>
			and relying on
			<a class="underline" href="https://huggingface.co/docs/datasets/repository_structure">automated data support</a>
			(you can use
			<a class="underline" href="https://huggingface.co/docs/datasets/main/en/cli#convert-to-parquet"><code>convert_to_parquet</code></a>
			from the <code>datasets</code> library). If this is not possible, please
			<a class="underline" href="/datasets/jaydeyoung/evidence_infer_treatment/discussions/new?title=Dataset+Viewer+issue%3A+DatasetWithScriptNotSupportedError&amp;description=The+dataset+viewer+is+not+working.%0A%0AError+details%3A%0A%0A%60%60%60%0AError+code%3A+++DatasetWithScriptNotSupportedError%0A%0A%60%60%60%0A%0A%0A---%0A%0A%F0%9F%91%8B+Before+opening+the+discussion%2C+have+you+considered+removing+the+%5Bloading+script%5D%28https%3A%2F%2Fhuggingface.co%2Fdocs%2Fdatasets%2Fdataset_script%29+and+relying+on+%5Bautomated+data+support%5D%28https%3A%2F%2Fhuggingface.co%2Fdocs%2Fdatasets%2Frepository_structure%29%3F%0A%0AYou+can+use+%5Bconvert_to_parquet%5D%28https%3A%2F%2Fhuggingface.co%2Fdocs%2Fdatasets%2Fmain%2Fen%2Fcli%23convert-to-parquet%29+from+the+datasets+library.%0A%0A---%0A%0A%0Acc+%40albertvillanova+%40lhoestq+%40severo.">open a discussion</a>
			for direct help.
		</p></div></div></div>

				
					<div class="SVELTE_HYDRATER contents" data-target="RepoCodeCopy" data-props="{}"><div></div></div>
					

					<div class="SVELTE_HYDRATER contents" data-target="SideNavigation" data-props="{&quot;titleTree&quot;:[{&quot;id&quot;:&quot;dataset-structure&quot;,&quot;label&quot;:&quot;Dataset Structure&quot;,&quot;children&quot;:[{&quot;id&quot;:&quot;data-instances&quot;,&quot;label&quot;:&quot;Data Instances&quot;,&quot;children&quot;:[],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Data Instances&quot;},{&quot;id&quot;:&quot;data-fields&quot;,&quot;label&quot;:&quot;Data Fields&quot;,&quot;children&quot;:[],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Data Fields&quot;},{&quot;id&quot;:&quot;data-splits&quot;,&quot;label&quot;:&quot;Data Splits&quot;,&quot;children&quot;:[],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Data Splits&quot;}],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Dataset Structure&quot;},{&quot;id&quot;:&quot;dataset-creation&quot;,&quot;label&quot;:&quot;Dataset Creation&quot;,&quot;children&quot;:[{&quot;id&quot;:&quot;curation-rationale&quot;,&quot;label&quot;:&quot;Curation Rationale&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Curation Rationale&quot;},{&quot;id&quot;:&quot;source-data&quot;,&quot;label&quot;:&quot;Source Data&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Source Data&quot;},{&quot;id&quot;:&quot;annotations&quot;,&quot;label&quot;:&quot;Annotations&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Annotations&quot;},{&quot;id&quot;:&quot;personal-and-sensitive-information&quot;,&quot;label&quot;:&quot;Personal and Sensitive Information&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Personal and Sensitive Information&quot;}],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Dataset Creation&quot;},{&quot;id&quot;:&quot;considerations-for-using-the-data&quot;,&quot;label&quot;:&quot;Considerations for Using the Data&quot;,&quot;children&quot;:[{&quot;id&quot;:&quot;social-impact-of-dataset&quot;,&quot;label&quot;:&quot;Social Impact of Dataset&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Social Impact of Dataset&quot;},{&quot;id&quot;:&quot;discussion-of-biases&quot;,&quot;label&quot;:&quot;Discussion of Biases&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Discussion of Biases&quot;},{&quot;id&quot;:&quot;other-known-limitations&quot;,&quot;label&quot;:&quot;Other Known Limitations&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Other Known Limitations&quot;}],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Considerations for Using the Data&quot;},{&quot;id&quot;:&quot;additional-information&quot;,&quot;label&quot;:&quot;Additional Information&quot;,&quot;children&quot;:[{&quot;id&quot;:&quot;dataset-curators&quot;,&quot;label&quot;:&quot;Dataset Curators&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Dataset Curators&quot;},{&quot;id&quot;:&quot;licensing-information&quot;,&quot;label&quot;:&quot;Licensing Information&quot;,&quot;children&quot;:[],&quot;isValid&quot;:false,&quot;title&quot;:&quot;Licensing Information&quot;},{&quot;id&quot;:&quot;citation-information&quot;,&quot;label&quot;:&quot;Citation Information&quot;,&quot;children&quot;:[],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Citation Information&quot;},{&quot;id&quot;:&quot;contributions&quot;,&quot;label&quot;:&quot;Contributions&quot;,&quot;children&quot;:[],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Contributions&quot;}],&quot;isValid&quot;:true,&quot;title&quot;:&quot;Additional Information&quot;}],&quot;classNames&quot;:&quot;top-6&quot;}">

<div class="absolute -left-12 bottom-0 top-0 z-10 top-6"><div class="sticky top-4 flex"><div class="h-7 pt-[0.175rem]">
				<span class="peer" tabindex="0"><button class="select-none hover:cursor-pointer"><svg width="1em" height="1em" viewBox="0 0 10 10" class="text-lg opacity-80 hover:opacity-100" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" focusable="false" role="img" preserveAspectRatio="xMidYMid meet" fill="currentColor"><path fill-rule="evenodd" clip-rule="evenodd" d="M1.65039 2.9999C1.65039 2.8066 1.80709 2.6499 2.00039 2.6499H8.00039C8.19369 2.6499 8.35039 2.8066 8.35039 2.9999C8.35039 3.1932 8.19369 3.3499 8.00039 3.3499H2.00039C1.80709 3.3499 1.65039 3.1932 1.65039 2.9999ZM1.65039 4.9999C1.65039 4.8066 1.80709 4.6499 2.00039 4.6499H8.00039C8.19369 4.6499 8.35039 4.8066 8.35039 4.9999C8.35039 5.1932 8.19369 5.3499 8.00039 5.3499H2.00039C1.80709 5.3499 1.65039 5.1932 1.65039 4.9999ZM2.00039 6.6499C1.80709 6.6499 1.65039 6.8066 1.65039 6.9999C1.65039 7.1932 1.80709 7.3499 2.00039 7.3499H8.00039C8.19369 7.3499 8.35039 7.1932 8.35039 6.9999C8.35039 6.8066 8.19369 6.6499 8.00039 6.6499H2.00039Z"></path></svg></button></span>
				<div class="invisible w-0 -translate-x-24 -translate-y-6 overflow-hidden rounded-xl border bg-white transition-transform hover:visible hover:w-52 hover:translate-x-0 peer-focus-within:visible peer-focus-within:w-52 peer-focus-within:translate-x-0"><nav aria-label="Secondary" class="max-h-[550px] overflow-y-auto p-3"><ul><li class="mb-3 text-sm last:mb-0"><a class="mb-1 block break-words font-semibold text-gray-700 *:break-words hover:underline active:text-gray-900 dark:active:text-gray-200" href="#dataset-structure" title="Dataset Structure"><!-- HTML_TAG_START -->Dataset Structure<!-- HTML_TAG_END --></a>
									<ul class="pl-1"><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-500" href="#data-instances" title="Data Instances"><!-- HTML_TAG_START -->Data Instances<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-500" href="#data-fields" title="Data Fields"><!-- HTML_TAG_START -->Data Fields<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-500" href="#data-splits" title="Data Splits"><!-- HTML_TAG_START -->Data Splits<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li></ul>
								</li><li class="mb-3 text-sm last:mb-0"><a class="mb-1 block break-words font-semibold text-gray-700 *:break-words hover:underline active:text-gray-900 dark:active:text-gray-200" href="#dataset-creation" title="Dataset Creation"><!-- HTML_TAG_START -->Dataset Creation<!-- HTML_TAG_END --></a>
									<ul class="pl-1"><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#curation-rationale" title="Curation Rationale"><!-- HTML_TAG_START -->Curation Rationale<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#source-data" title="Source Data"><!-- HTML_TAG_START -->Source Data<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#annotations" title="Annotations"><!-- HTML_TAG_START -->Annotations<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#personal-and-sensitive-information" title="Personal and Sensitive Information"><!-- HTML_TAG_START -->Personal and Sensitive Information<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li></ul>
								</li><li class="mb-3 text-sm last:mb-0"><a class="mb-1 block break-words font-semibold text-gray-700 *:break-words hover:underline active:text-gray-900 dark:active:text-gray-200" href="#considerations-for-using-the-data" title="Considerations for Using the Data"><!-- HTML_TAG_START -->Considerations for Using the Data<!-- HTML_TAG_END --></a>
									<ul class="pl-1"><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#social-impact-of-dataset" title="Social Impact of Dataset"><!-- HTML_TAG_START -->Social Impact of Dataset<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#discussion-of-biases" title="Discussion of Biases"><!-- HTML_TAG_START -->Discussion of Biases<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#other-known-limitations" title="Other Known Limitations"><!-- HTML_TAG_START -->Other Known Limitations<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li></ul>
								</li><li class="mb-3 text-sm last:mb-0"><a class="mb-1 block break-words font-semibold text-gray-700 *:break-words hover:underline active:text-gray-900 dark:active:text-gray-200" href="#additional-information" title="Additional Information"><!-- HTML_TAG_START -->Additional Information<!-- HTML_TAG_END --></a>
									<ul class="pl-1"><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#dataset-curators" title="Dataset Curators"><!-- HTML_TAG_START -->Dataset Curators<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-300 dark:text-gray-700" href="#licensing-information" title="Licensing Information"><!-- HTML_TAG_START -->Licensing Information<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-500" href="#citation-information" title="Citation Information"><!-- HTML_TAG_START -->Citation Information<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li><li><a class="mb-0.5 block break-words hover:underline active:text-gray-700 dark:active:text-gray-300 text-gray-500" href="#contributions" title="Contributions"><!-- HTML_TAG_START -->Contributions<!-- HTML_TAG_END --></a>
												<ul class="pl-2"></ul>
											</li></ul>
								</li></ul></nav></div></div></div></div></div>
					<div class="2xl:pr-6"><div class="prose pl-6 -ml-6 hf-sanitized hf-sanitized-92BHJpb99QpTJgzjNqflV">
	<!-- HTML_TAG_START --><h1 class="relative group flex items-center">
	<a rel="nofollow" href="#dataset-card-for-evidence-infer" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="dataset-card-for-evidence-infer">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Dataset Card for Evidence Infer
	</span>
</h1>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#dataset-summary" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="dataset-summary">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Dataset Summary
	</span>
</h3>
<p>Data and code from our "Inferring Which Medical Treatments Work from Reports of Clinical Trials", NAACL 2019. This work concerns inferring the results reported in clinical trials from text.</p>
<p>The dataset consists of biomedical articles describing randomized control trials (RCTs) that compare multiple treatments. Each of these articles will have multiple questions, or 'prompts' associated with them. These prompts will ask about the relationship between an intervention and comparator with respect to an outcome, as reported in the trial. For example, a prompt may ask about the reported effects of aspirin as compared to placebo on the duration of headaches. For the sake of this task, we assume that a particular article will report that the intervention of interest either significantly increased, significantly decreased or had significant effect on the outcome, relative to the comparator.</p>
<p>The dataset could be used for automatic data extraction of the results of a given RCT. This would enable readers to discover the effectiveness of different treatments without needing to read the paper.</p>
<p>We have recently collected additional data for this task (<a rel="nofollow" href="https://arxiv.org/abs/2005.04177">https://arxiv.org/abs/2005.04177</a>), which we will present at BioNLP 2020.</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#supported-tasks-and-leaderboards" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="supported-tasks-and-leaderboards">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Supported Tasks and Leaderboards
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#languages" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="languages">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Languages
	</span>
</h3>
<ul>
<li>English (<code>en</code>).</li>
</ul>
<h2 class="relative group flex items-center">
	<a rel="nofollow" href="#dataset-structure" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="dataset-structure">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Dataset Structure
	</span>
</h2>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#data-instances" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="data-instances">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Data Instances
	</span>
</h3>
<pre><code>{'Text': "TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)\n\n  ABSTRACT.AIM:\nTo compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n â‰¥ 228) or placebo (n = 114) with glimepiride (2â€“4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes.\n\nABSTRACT.METHODS:\nIn total, 1041 adults (mean Â± sd), age 56 Â± 10 years, weight 82 Â± 17 kg and glycated haemoglobin (HbA1c) 8.4 Â± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study.\n\nABSTRACT.RESULTS:\nLiraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (âˆ’0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (âˆ’0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (âˆ’0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (âˆ’0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P &lt; 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (&lt; 10%), nausea (&lt; 11%), vomiting (&lt; 5%) and diarrhoea (&lt; 8%).\n\nABSTRACT.CONCLUSIONS:\nLiraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.\n\nBODY.INTRODUCTION:\nMost drugs that target Type 2 diabetes (T2D) also cause weight gain or hypoglycaemia, or both, with the risk increasing with combination therapy. Glucagon-like peptide-1 (GLP-1)-based therapies stimulate insulin secretion and reduce glucagon secretion only during hyperglycaemia. GLP-1 also slows gastric emptying and reduces appetite [1].  Although American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines recommend lifestyle and metformin as initial therapy for T2D [2], sulphonylureas are used widely, particularly when metformin or thiazolidinediones are not tolerated. Glycaemic control eventually deteriorates with sulphonylureas while hypoglycaemia and weight gain are common [3]. Incretin therapy improves glycaemic control with low hypoglycaemic risk, while delayed gastric emptying and reduced appetite can reduce weight [1,4].  Liraglutide is a once-daily human GLP-1 analogue with 97% linear amino-acid sequence homology to human GLP-1 [5] and half-life of 13 h after subcutaneous administration that produces 24-h blood glucose control [6]. Liraglutide monotherapy for 14 weeks reduced glycated haemoglobin (HbA1c) by 1.7% and fasting plasma glucose (FPG) by 3.4 mmol/l without causing hypoglycaemia, along with weight loss (âˆ¼3 kg) compared with placebo [7]. Improvements in pancreatic B-cell function [7â€“9] and blood pressure [7], along with decreased glucagon secretion [7,10], also occurred. As part of the phase 3 programme [the Liraglutide Effect and Action in Diabetes (LEAD) programme] with liraglutide in &gt; 4000 subjects with T2D as monotherapy or in combination therapy, this 26-week trial examined liraglutide plus glimepiride compared with either placebo or rosiglitazone added to glimepiride on glycaemic control and body weight.\n\nBODY.SUBJECTS AND METHODS.STUDY PARTICIPANTS:\nInclusion criteria: T2D treated with oral glucose-lowering agents (OGLAs) for â‰¥ 3 months; 18â€“80 years of age; HbA1c 7.0â€“11.0% (previous OGLA monotherapy) or 7.0â€“10.0% (previous OGLA combination therapy); body mass index (BMI) â‰¤ 45.0 kg/m2. Exclusion criteria: used insulin within 3 months, impaired liver or renal function, uncontrolled hypertension (â‰¥ 180/100 mmHg), cancer or used any drugs apart from OGLAs likely to affect glucose concentrations. Subjects provided written informed consent. The study was conducted in accordance with good clinical practice guidelines and approved by independent ethics committees.\n\nBODY.SUBJECTS AND METHODS.STUDY DESIGN:\nThe study was a 26-week, double-blind, double-dummy, randomized, active-control, five-armed parallel (116 sites in 21 countries, primarily Europe and Asia) trial enrolling 1041 subjects (1â€“37 subjects per centre), all receiving glimepiride (2â€“4 mg/day) in combination with (Fig. 1):  FIGURE 1Overview of trial design and treatment arms.  one of three liraglutide doses [0.6, 1.2 or 1.8 mg, injected subcutaneously (Novo Nordisk, Bagsvaerd, Denmark) and rosiglitazone placebo];liraglutide placebo and rosiglitazone placebo;liraglutide placebo and rosiglitazone 4 mg/day (rosiglitazone; AvandiaTM; GlaxoSmithKline, London, UK).  The doses of rosiglitazone and glimepiride used were determined by the highest doses approved in all participating counties. After discontinuing previous OGLAs except glimepiride, separate 2-week titration and maintenance periods with glimepiride (open-label) preceded randomization (Fig. 1). Subjects were stratified according to previous treatment (monotherapy or combination therapy). After randomization, 2-week treatment titration and 24-week treatment (maintenance) phases (Fig. 1) were completed. Liraglutide was up-titrated weekly in 0.6-mg increments until allocated doses were reached. Glimepiride could be adjusted between 2 and 4 mg/day in case of hypoglycaemia or other adverse events (AEs), while other drug doses were fixed. Liraglutide (active and placebo) was supplied in 3-ml pre-filled pens with 31G needles (Novo Nordisk). Subjects were encouraged to inject liraglutide into the upper arm, thigh or abdomen at the same time each day. Rosiglitazone and glimepiride were taken in the morning or with the first meal.\n\nBODY.SUBJECTS AND METHODS.STUDY MEASUREMENTS.EFFICACY:\nThe primary endpoint was change from baseline HbA1c after 26 weeks of treatment. Secondary endpoints included: percentages of subjects reaching HbA1c (&lt; 7.0%, â‰¤ 6.5%), FPG (5.0 to â‰¤ 7.2 mmol/l) and postprandial plasma glucose (PPG; 10.0 mmol/l) targets [11â€“13]; changes in body weight, FPG, mean PPG, indices of pancreatic B-cell function [pro-insulin : insulin ratio and homeostasis model assessment (HOMA)-B], HOMA-insulin resistance (HOMA-IR) and blood pressure (BP).  HbA1c was measured centrally (MDS Pharma Services, King of Prussia, PA, USA) by high performance liquid chromatography while plasma glucose (PG) was self-measured using MediSenseÂ® glucose meters (Abbott Diagnostics Inc., Abbott Park, IL, USA). Insulin and C-peptide were measured by chemiluminescence, proinsulin by ELISA, while glucagon was measured in aprotinin-treated plasma by radioimmunoassay. The proinsulin : insulin ratio was calculated from fasting insulin and fasting proinsulin. HOMA-B and HOMA-IR were both calculated from FPG and fasting insulin. Samples measured centrally were collected and transported according to detailed procedures in the MDS Pharma Services manual. Samples stored at ambient temperature were shipped by courier to the central laboratory on the same day as collection, while frozen samples were shipped every 3 weeks.\n\nBODY.SUBJECTS AND METHODS.STUDY MEASUREMENTS.SAFETY:\nSafety variables included hypoglycaemic episodes based on PG levels (&lt; 3.1 mmol/l), liraglutide antibodies including cross-reacting and neutralizing antibodies, tolerability (gastrointestinal complaints) and pulse. AEs, vital signs, electrocardiogram (ECG), biochemical and haematology measures including calcitonin were also monitored. Self-treated hypoglycaemic episodes were classified as minor, while those requiring third-party assistance were considered major. Serum antibodies against liraglutide were measured by radioimmunoprecipitation assay.\n\nBODY.SUBJECTS AND METHODS.STATISTICAL ANALYSES:\nAll efficacy and safety analyses were based on intent-to-treat criteria, defined as subjects who were exposed to â‰¥ 1 dose of trial product(s). Efficacy endpoints were analysed by ancova with treatment, country and previous glucose-lowering treatment as fixed effects and baseline values as covariates. Missing data were imputed by last observation carried forward (LOCF). Sample size calculations were based on predicted HbA1c and body weight after trial completion. As the three liraglutide + glimepiride groups were to be compared with both rosiglitazone + glimepiride and glimepiride monotherapy, two calculations were performed. These sample size calculations assumed a standard deviation of 1.2% of HbA1c, the non-inferiority/superiority margin vs. active control was set to 0.4% and the difference to detect (superiority vs. placebo) was set to 0.5%. For body weight, a coefficient of variation of 3% (based on phase 2a trials for liraglutide) and a difference to detect of 3% were assumed. A combined power (calculated as the product of the marginal powers for HbA1c and body weight) of at least 85% was required. These calculations indicated that at least 168 and 81 patients completing the study would be needed for the combination and glimepiride monotherapy groups, respectively. Assuming a drop-out rate of 25%, targets for randomization were 228 in each of the combination therapy groups and 114 in the placebo group (total n = 1026).  To protect against Type 1 errors, HbA1c was analysed using hierarchical testing for descending doses of liraglutide. First, superiority of liraglutide 1.8 mg to placebo was tested and, only if superior to placebo, non-inferiority to rosiglitazone was tested. If non-inferiority was obtained, superiority to rosiglitazone for liraglutide 1.8 mg was tested and superiority to placebo for liraglutide 1.2 mg was tested. If superiority was confirmed, non-inferiority to rosiglitazone would be tested and so on (i.e. testing sequence was stopped when hypotheses could not be rejected). Superiority was concluded when upper limits of two-sided 95% confidence intervals (CIs) for treatment differences were below 0%; non-inferiority was concluded if these values were &lt; 0.4%; for secondary endpoints, Type 1 errors were controlled by estimating simultaneous CIs using Dunnett's method.  Proportions of subjects achieving HbA1c (HbA1c &lt; 7.0%, and â‰¤ 6.5%) and FPG (5.0 â‰¤ FPG â‰¤ 7.2 mmol/l) targets [13] were compared between treatments using logistic regression with allocated treatment and baseline values as covariates. Chi-square analyses assessed differences in treatments for percentages of subjects achieving no, one, two or three PPG values &lt; 10 mmol/l [13]. Hypoglycaemic episodes were analysed under the assumption that number per subject were negatively binomially distributed using a generalized linear model, including treatment and country as fixed effects. Other safety data were compared by descriptive statistics. Values for descriptive statistics are expressed as means Â± sd, while ancova results are expressed as least square means Â± SEM or with 95% CI unless otherwise noted. Significance levels were set to 5% for two-sided tests and 2.5% for one-sided tests.\n\nBODY.RESULTS.DISPOSITION AND DEMOGRAPHICS:\nThe treatment groups were well balanced (Table 1). Of 1712 subjects screened, 1041 were randomized and 1040 were exposed to trial drugs; 147 subjects (14.1%) withdrew (Fig. 2). Withdrawals were higher with placebo (27%) and rosiglitazone treatment (16%) compared with liraglutide 0.6 mg (11%), liraglutide 1.2 mg (14%) and liraglutide 1.8 mg (9%) treatment. Thirty-eight subjects (3.7%) withdrew as a result of AEs (Fig. 2).   Table 1 Demographic characteristics of study participants Liraglutide 0.6 mg ( n  = 233) Liraglutide 1.2 mg ( n  = 228) Liraglutide 1.8 mg ( n  = 234) Placebo ( n  = 114) Rosiglitazone ( n  = 232) Male : female (%) 54 : 46 45 : 55 53 : 47 47 : 53 47 : 53 Age (years) 55.7 Â± 9.9 57.7 Â± 9.0 55.6 Â± 10.0 54.7 Â± 10.0 56.0 Â± 9.8 Duration of diabetes (years) 6.5 (4.0,10.2) 6.7 (4.0,10.7) 6.5 (3.7,10.5) 6.5 (4.5,10.6) 6.6 (4.3,10.7) Previous on mono : combi (%) 30 : 70 31 : 69 27 : 73 32 : 68 32 : 68 FPG (mmol/l) 10.0 Â± 2.4 9.8 Â± 2.7 9.7 Â± 2.4 9.5 Â± 2.0 9.9 Â± 2.5 HbA 1c  (%) 8.4 Â± 1.0 8.5 Â± 1.1 8.5 Â± 0.9 8.4 Â± 1.0 8.4 Â± 1.0 Diabetic retinopathy (%) 17.2 14.9 12.0 13.2 16.4 Hypertension (%) 69.1 68.0 69.7 64.9 66.8 BMI (kg/m 2 ) 30.0 Â± 5.0 29.8 Â± 5.1 30.0 Â± 5.1 30.3 Â± 5.4 29.4 Â± 4.8 Weight (kg) 82.6 Â± 17.7 80.0 Â± 17.1 83.0 Â± 18.1 81.9 Â± 17.1 80.6 Â± 17.0 Systolic blood pressure (mmHg) 131 Â± 16 133 Â± 15 132 Â± 16 131 Â± 15.3 133 Â± 15 Data are mean Â±  sd  and percentages, except for duration of diabetes, where data are median, 25th and 75th percentile. BMI, body mass index; FPG, fasting plasma glucose; HbA 1c , glycated haemoglobin; mono : combi, previous treatment with either monotherapy or combination therapy;  sd , standard deviation.   FIGURE 2Flow of patients through the study.\n\nBODY.RESULTS.EFFICACY.HBA:\nHbA1c decreased rapidly with all doses of liraglutide when added to glimepiride compared with either rosiglitazone or placebo (i.e. glimepiride monotherapy), irrespective of previous therapy. The greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3aâ€“c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone. Rosiglitazone also was superior to placebo (P &lt; 0.0001).  FIGURE 3Mean glycated haemoglobin (HbA1c) by treatment and week (intent-to-treat population with last observation carried forward): (a) overall population; (b) previously on monotherapy; or (c) previously on combination therapy; (d) mean changes in HbA1c from baseline after 26 weeks of treatment. Keys: (aâ€“c) liraglutide 0.6 mg: grey dotted line with squares; liraglutide 1.2 mg: black solid line with triangles; liraglutide 1.8 mg: black dotted line with squares; rosiglitazone: grey solid line with circles; placebo: black solid line with circles. (d) liraglutide 0.6 mg: black stripes on white; liraglutide 1.2 mg: white stripes on black, liraglutide 1.8 mg: grey tint; rosiglitazone: white; placebo: black. ****P &lt; 0.0001 compared with placebo; â€ â€ â€ â€ P &lt; 0.0001 compared with rosiglitazone.  HbA1c decreases were greater for subjects who entered from monotherapy compared with combination therapy (Fig. 3d). However, because the increase with placebo was higher for individuals entering on combination therapy (0.7 vs. 0.23%), the differences between treatment groups in favour of liraglutide were similar irrespective of whether subjects were treated previously with monotherapy or combination therapy. Neither age, gender nor BMI affected these trends.\n\nBODY.RESULTS.EFFICACY.PERCENTAGE REACHING AN HBA:\nThe percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  FIGURE 4Subjects achieving specified glycated haemoglobin (HbA1c) levels: (a) percentage reaching HbA1c &lt; 7.0% (American Diabetes Association/European Association for the Study of Diabetes target); (b) percentage reaching HbA1c &lt; 6.5% (International Diabetes Federation/American Association of Clinical Endocrinologists targets); (c) cumulative distribution of HbA1c at 26 weeks for the intent-to-treat (ITT) population; and (d) for the ITT last observation carried forward (LOCF) population. Keys: (a, b) liraglutide 0.6 mg: black stripes on white; liraglutide 1.2 mg: white stripes on black, liraglutide 1.8 mg: grey tint; rosiglitazone: white; placebo: black. (c, d) liraglutide 0.6 mg: pale grey solid line; liraglutide 1.2 mg: grey solid line, liraglutide 1.8 mg: black solid line; rosiglitazone: dotted black line; placebo: dotted grey line; baseline visit: long dashed black line. ****P &lt; 0.0001 or **P &lt; 0.01 compared with placebo; â€ â€ â€ â€ P &lt; 0.0001 or â€ â€ â€ P = 0.0005 compared with rosiglitazone.\n\nBODY.RESULTS.EFFICACY.FASTING PLASMA GLUCOSE:\nBy week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg. An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P â‰¤ 0.006) after 26 weeks.  FIGURE 5Mean changes from baseline in fasting plasma glucose after 26 weeks of treatment. ****P &lt; 0.0001 compared with placebo; â€ â€ P &lt; 0.01 compared with rosiglitazone.  The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).\n\nBODY.RESULTS.EFFICACY.POSTPRANDIAL PLASMA GLUCOSE:\nPPG was reduced similarly after each meal. The greatest reductions in mean PPG values from baseline (average of values obtained 90 min after breakfast, lunch and evening meal) occurred with liraglutide 1.2 mg (2.5 mmol/l) and liraglutide 1.8 mg (2.7 mmol/l). By comparison, the reduction from baseline in mean PPG values was 1.8 mmol/l for rosiglitazone and liraglutide 0.6 mg and 0.4 mmol/l for placebo. Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.\n\nBODY.RESULTS.EFFICACY.PPG MEASUREMENTS &lt; 10.0 MMOL/L:\nThe percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.\n\nBODY.RESULTS.BODY WEIGHT:\nMean weight at baseline was 81.6 kg. Mean reductions in weight from baseline to end of treatment were 0.2 kg with liraglutide 1.8 mg and 0.1 kg with placebo treatment, while increases occurred with either liraglutide 0.6 mg (0.7 kg), liraglutide 1.2 mg (0.3 kg) or rosiglitazone (2.1 kg) (Fig. 6). Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (âˆ’2.3 to âˆ’1.4 kg; P &lt; 0.0001), although there were no significant differences compared with placebo. Gender appeared to have no influence on the results, as indicated when added as a fixed effect in the ancova model.  FIGURE 6Mean changes in body weight from baseline after 26 weeks of treatment. *P &lt; 0.05 compared with placebo; â€ â€ â€ â€ P &lt; 0.0001 compared with rosiglitazone.\n\nBODY.RESULTS.INDICES OF PANCREATIC B-CELL FUNCTION AND INSULIN RESISTANCE:\nReductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051). There were no significant differences between treatments for HOMA-IR.   Table 2 Selected indices of pancreatic B-cell function Variable Treatment Baseline Week 26 (LOCF) Least square difference from placebo (95% CI) Least square difference from rosiglitazone (95% CI) Proinsulin : insulin ratio Liraglutide 0.6 mg 0.42 Â± 0.22 0.38 Â± 0.24 âˆ’0.05 (âˆ’0.11; 0.00) âˆ’0.02 (âˆ’0.06; 0.03) Liraglutide 1.2 mg 0.45 Â± 0.31 0.33 Â± 0.20 âˆ’0.10 (âˆ’0.16; âˆ’0.05) â€  âˆ’0.07 (âˆ’0.11; âˆ’0.02) * Liraglutide 1.8 mg 0.48 Â± 0.33 0.36 Â± 0.20 âˆ’0.09 (âˆ’0.15; âˆ’0.03) * âˆ’0.05 (âˆ’0.10; âˆ’0.01) * Placebo 0.44 Â± 0.27 0.46 Â± 0.29 Rosiglitazone 0.45 Â± 0.29 0.40 Â± 0.20 HOMA-B (%) Liraglutide 0.6 mg 51 Â± 43.3 70 Â± 88.6 15 (âˆ’19.10; 49.0) 11 (âˆ’16.7; 39.0) Liraglutide 1.2 mg 71 Â± 254.3 99 Â± 184.3 43 (8.10; 76.9) * 39 (10.3; 67.0) * Liraglutide 1.8 mg 56 Â± 84.6 91 Â± 108.2 34 (âˆ’0.23; 68.5) 30 (2.00; 58.6) * Placebo 56 Â± 103.3 52 Â± 107.3 Rosiglitazone 46 Â± 36.2 59 Â± 63.3 * P â‰¤ 0.05; â€  P  &lt; 0.0001. CI, confidence interval; HOMA, homeostatis model assessment; LOCF, last observation carried forward. \n\nBODY.RESULTS.BLOOD PRESSURE AND PULSE:\nAlthough decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).\n\nBODY.RESULTS.SAFETY:\nThe most common treatment-emergent AEs that were considered by investigators to be either possibly or probably related to liraglutide were gastrointestinal (diarrhoea, nausea, dyspepsia and constipation) and nervous system disorders (headache and dizziness), particularly during the first 4 weeks. Nausea was highest with liraglutide 1.2 mg (10.5%) and lowest with placebo (1.8%). Vomiting (4.4%) and diarrhoea (7.9%) were also higher with liraglutide 1.2 mg. Withdrawals because of nausea ranged from 0.9â€“2.2%, vomiting 0.4â€“0.9% and diarrhoea 0â€“1.3%.  Nausea was more common with liraglutide compared with placebo and rosiglitazone, particularly during the first 4 weeks (Fig. 7). Frequency of nausea was less in the liraglutide 0.6 mg treatment group compared with the higher doses of liraglutide. Generally, the occurrence of nausea dissipated from 4 to 26 weeks of treatment in all groups using liraglutide (Fig. 7).  FIGURE 7Percentage of subjects experiencing nausea over the course of the study. Key: liraglutide 0.6 mg with glimepiride: black line with filled circles; liraglutide 1.2 mg with glimepiride: black line with filled triangles; liraglutide 1.8 mg with glimepiride: grey line with hollow circles; glimepiride grey lines with filled squares; rosiglitazone and glimepiride: grey line with hollow triangles.  The incidence of serious AEs ranged between 3 and 5%: placebo (3%), rosiglitazone (3%), liraglutide 0.6 mg (3%), liraglutide 1.2 mg (4%) and liraglutide 1.8 mg (5%). Most treatment-emergent serious AEs were judged by investigators to be unlikely to be related to trial products. No deaths were reported during the trial. One subject developed chronic pancreatitis whilst taking liraglutide 0.6 mg; the person had no reported previous history of pancreatitis. The subject continued on liraglutide therapy and completed the trial. At screening, five patients had been previously diagnosed with pancreatitis. As pancreatitis was not an exclusion criterion, these patients were randomized as follows: one to liraglutide 0.6 mg, one to liraglutide 1.2 mg, two to liraglutide 1.8 mg and one to rosiglitazone + glimepiride. All five patients completed the trial without reporting pancreatitis as an adverse event.  Hypoglycaemia was infrequent with all treatments. One major hypoglycaemic episode (self-measured blood glucose = 3.0 mmol/l) occurred 9 days after treatment started in a subject receiving liraglutide 1.8 mg in combination with glimepiride. Although medical assistance was not needed, the subject required third-party assistance. The investigator judged the episode as likely to be related to glimepiride and reduced the dose from 4 to 3 mg after the incident.  Minor hypoglycaemia occurred in &lt; 10% of subjects for any treatment. The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.  Antibodies to liraglutide were found in 9â€“13% of subjects treated with liraglutide. No significant effects of these antibodies on HbA1c were found in pooled analyses of four trials including the current study. There were no clinically relevant changes in ophthalmoscopy, biochemistry, urinalysis, haematology or ECG assessments. No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.\n\nBODY.DISCUSSION:\nTreatment with liraglutide plus glimepiride was superior to glimepiride monotherapy at all doses of liraglutide and superior to rosiglitazone plus glimepiride for the two higher liraglutide doses for improving HbA1c. Similar findings for reductions in FPG and PPG highlight improved 24-h glucose control with once-daily liraglutide, with substantially more subjects reaching glycaemic targets, particularly with liraglutide 1.8 mg. Improvements in pancreatic B-cell function were larger with liraglutide 1.2 and 1.8 mg compared with rosiglitazone. Liraglutide was well tolerated and occurrence of gastrointestinal AEs was low overall, particularly after week 4.  Although rates of hypoglycaemia were low in all treatment groups (&lt; 10%), minor hypoglycaemic events occurred more often in patients treated with glimepiride plus liraglutide 1.2 or 1.8 mg than with glimepiride alone. It should be noted, however, that patients treated with liraglutide 1.2 or 1.8 mg achieved a lower HbA1c than those receiving glimepiride monotherapy. At lower HbA1c levels, sulphonylureas are known to elicit hypoglycaemia more readily than at higher levels. In clinical practice it may be possible to reduce the dose of sulphonylurea (when used with liraglutide) to minimize risk of hypoglycaemia and maintain HbA1cimprovements.  Although weight effects were modest, liraglutide produced more favourable weight effects compared with rosiglitazone, which produced substantial weight gain. In other studies with liraglutide, subjects adding a 1.8-mg dose to metformin lost 2.8 kg [14], while those adding both metformin and glimepiride lost 1.8 kg compared with placebo [15] (both over 26 weeks) and those on liraglutide monotherapy (1.8 mg) lost 2.45 kg over 52 weeks [16]. In our study, because sulphonylureas usually cause weight gain, inclusion or optimization of glimepiride but not metformin may have mitigated the weight benefits typically associated with liraglutide. Lack of weight effects could be secondary to lower baseline body weight, withdrawal of previous metformin treatment or defensive snacking to minimize risk of hypoglycaemia.  It might have been expected that the greater weight gain with rosiglitazone compared with liraglutide 1.8 mg would be associated with a concurrent increase in insulin resistance with rosiglitazone. The absence of this effect could reflect the insulin-sensitizing nature of rosiglitazone. Improvements in pancreatic B-cell function associated with liraglutide are consistent with other studies [7â€“9].  Study strengths include inclusion of both placebo and active (rosiglitazone) comparators and that OGLAs were optimized (not maximized) before randomization to minimize risk of hypoglycaemia. Limitations of the study include short duration of the trial and restriction on glimepiride and rosiglitazone in some countries that precluded maximal dosing.  The impact of using other GLP-1-based treatments [such as exenatide, or the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin] with sulphonylureas in subjects with T2D has been studied. In a 30-week American trial where exenatide twice a day was added to sulphonylureas, HbA1c was reduced by 0.46% from baseline with 5 Î¼g and 0.86% with 10 Î¼g [17] compared with 1.1% with liraglutide 1.8 or 1.2 mg. This reduction in HbA1c with liraglutide is consistent with other LEAD trials investigating liraglutide as monotherapy or in combination with various OGLA drugs. In these trials, HbA1c was reduced by 1â€“1.5%[14,16,18â€“20]. Reductions in FPG with exenatide were 0.3 and 0.6 mmol/l from baseline with 5 Î¼g and 10 Î¼g, respectively, compared with 1.4 mmol/l with liraglutide 1.8 mg; weight loss of 1.6 kg occurred with exenatide 10 Î¼g compared with 0.2 kg for liraglutide 1.8 mg [17]. Differences in weight effects may be as a result of lower baseline weight in this trial (82 kg) compared with exenatide (96 kg) and discontinuation of previous metformin therapy, unlike the exenatide trial where exenatide was added to previous sulphonylurea monotherapy [17]. Other large-scale trials with liraglutide in combination with sulphonylureas have demonstrated weight loss of 2â€“3 kg [18,20]. Withdrawals from exenatide trials ranged from 24â€“30% compared with 9â€“14% with liraglutide in this study. Nausea with exenatide ranged from 39% with 5 Î¼g to 51% with 10 Î¼g [17] compared with 10.5% for liraglutide. Furthermore, 41% were positive for anti-exenatide antibodies compared with 9â€“13% with anti-liraglutide antibodies.  With sitagliptin 100 mg once daily for 24 weeks, HbA1c decreased by 0.3% from baseline in subjects receiving glimepiride, with 11% achieving an HbA1c &lt; 7.0%[21]. Reductions in FPG and PPG from baseline were 0.05 and 1.4 mmol/l, respectively, while weight increased by 0.8 kg and the prevalence of nausea was &lt; 1%.  Although head-to-head trials are required to test true differences between these agents, the marked effects of liraglutide on FPG may be as a result of consistent blood levels of liraglutide maintained over 24 h compared with exenatide which has to be administered 60 min before breakfast and dinner and has a half-life of 1.5â€“3.6 h [22]. In a recent 26-week head-to-head trial comparing liraglutide with exenatide, liraglutide produced a 0.3% greater decrease on HbA1c (P &lt; 0.0001) [20]. Because DPP-4 inhibitors inhibit the degradation of GLP-1, the efficacy of sitagliptin is dependent on levels of endogenous GLP-1 which is physiologically low compared with the much higher pharmacological levels of liraglutide. Pharmacological levels may be needed to induce satiety, weight loss and possibly larger HbA1c reductions.  Liraglutide is an effective and well-tolerated once-daily human GLP-1 analogue that improves overall glycaemic control and indices of pancreatic B-cell function with minimal weight gain and risk of hypoglycaemia when used in combination with a sulphonylurea for T2D.\n\nBODY.COMPETING INTERESTS:\nThe study was funded by Novo Nordisk, the manufacturer of liraglutide. In collaboration with the investigators, Novo Nordisk was responsible for the study design, protocol, statistical analysis plans, oversight, analysis and reporting of the results. Data were recorded at the clinical centres and maintained by the sponsor. The LEAD-1 SU study group had full access to the data. Final responsibility for the decision to submit the manuscript for publication was the authors. MM has received lecture fees from Novo Nordisk, Servier, MSD; JS has received honoraria, grants and lecture fees from Novo Nordisk; MB, WMWB and NAK have no conflicts to declare; JS has received lecture fees from Novo Nordisk; MZ is employed by, and holds stock in, Novo Nordisk; TLT is employed by Novo Nordisk; SC is a member of the international advisory board on liraglutide for Novo Nordisk and has received lecture fees from Novo Nordisk.",
 'PMCID': 2871176,
 'Prompts': {'PromptID': [150,
   113,
   140,
   106,
   142,
   149,
   148,
   152,
   154,
   125,
   121,
   124,
   107,
   105,
   133,
   103,
   126,
   118,
   132,
   122,
   141,
   151,
   112,
   153,
   102,
   129,
   104,
   116,
   136,
   123,
   135,
   139,
   101,
   99,
   144,
   145,
   147,
   117,
   143,
   111,
   137,
   114,
   108,
   128,
   134,
   115,
   127,
   131,
   109,
   146,
   110,
   100,
   138,
   119,
   130],
  'PMCID': [2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176,
   2871176],
  'Outcome': ['Incidence of minor hypoglycaemia',
   'Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%',
   'HOMA-IR',
   'HbA1c level at 26 weeks',
   'Reductions in systolic blood pressure',
   'Pulse variations',
   'Pulse variations',
   'Incidence of minor hypoglycaemia',
   'Changes in calcitonin at week 26',
   'Postprandial plasma glucose',
   'ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l',
   'Postprandial plasma glucose',
   'HbA1c level at 26 weeks',
   'HbA1c level at 26 weeks',
   'Proinsulin : insulin ratio',
   'Postprandial plasma glucose',
   'ADA postprandial plasma glucose goals less than 10.0 mmol/l',
   'ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l',
   'Proinsulin : insulin ratio',
   'ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l',
   'Reductions in systolic blood pressure',
   'Incidence of minor hypoglycaemia',
   'Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%',
   'Changes in calcitonin at week 26',
   'Fasting plasma glucose at week 26',
   'ADA postprandial plasma glucose goals less than 10.0 mmol/l',
   'Postprandial plasma glucose',
   'Fasting plasma glucose at week 26',
   'HOMA-B',
   'Postprandial plasma glucose',
   'HOMA-B',
   'HOMA-IR',
   'Fasting plasma glucose at week 26',
   'HbA1c level at 26 weeks',
   'Reductions in systolic blood pressure',
   'Decreases in diastolic blood pressure',
   'Pulse variations',
   'Fasting plasma glucose at week 26',
   'Reductions in systolic blood pressure',
   'Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%',
   'HOMA-B',
   'Patients reaching HbA1c goals less than 7.0% ',
   'HbA1c level at 26 weeks',
   'ADA postprandial plasma glucose goals less than 10.0 mmol/l',
   'Proinsulin : insulin ratio',
   'Fasting plasma glucose at week 26',
   'ADA postprandial plasma glucose goals less than 10.0 mmol/l',
   'Proinsulin : insulin ratio',
   'HbA1c level at 26 weeks',
   'Decreases in diastolic blood pressure',
   'Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%',
   'HbA1c level at 26 weeks',
   'HOMA-B',
   'ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l',
   'Weight gain'],
  'Intervention': ['Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (0.6 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (1.8 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride ',
   'Rosiglitazone plus glimepiride',
   'Liraglutide (all doses) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Liraglutide (1.8 mg) plus glimepiride ',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Rosiglitazone plus glimepiride'],
  'Comparator': ['Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride ',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride ',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride ',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride ',
   'Liraglutide (1.2 mg) plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride ',
   'Placebo plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride ',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride',
   'Rosiglitazone plus glimepiride',
   'Placebo plus glimepiride ',
   'Placebo plus glimepiride',
   'Liraglutide plus glimepiride'],
  'Annotations': [{'UserID': [0, 3, 2],
    'PromptID': [150, 150, 150],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.'],
    'Label Code': [1, 1, 1],
    'In Abstract': [True, True, True],
    'Evidence Start': [25524, 25964, 25964],
    'Evidence End': [26184, 26073, 26184]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [113, 113, 113, 113],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003)',
     'he estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  ',
     'The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), ',
     'The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [16120, 16121, 16120, 16120],
    'Evidence End': [16353, 16449, 16355, 16449]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [140, 140, 140, 140],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['There were no significant differences between treatments for HOMA-IR.',
     'There were no significant differences between treatments for HOMA-IR.',
     'There were no significant differences between treatments for HOMA-IR.',
     'There were no significant differences between treatments for HOMA-IR.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20943, 20943, 20943, 20943],
    'Evidence End': [21012, 21012, 21012, 21012]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [106, 106, 106, 106],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['All liraglutide doses were superior to placebo (P &lt; 0.0001)',
     'Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). ',
     'All liraglutide doses were superior to placebo (P &lt; 0.0001),',
     'All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001).'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [14169, 13955, 14169, 14169],
    'Evidence End': [14228, 14314, 14229, 14313]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [142, 142, 142, 142],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg)',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg)',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22039, 22039, 22039, 22039],
    'Evidence End': [22230, 22232, 22230, 22232]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [149, 149, 149, 149],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).',
     'Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002)',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22554, 22554, 22373, 22554],
    'Evidence End': [22738, 22738, 22640, 22738]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [148, 148, 148, 148],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002)',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).',
     'Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22554, 22554, 22554, 22373],
    'Evidence End': [22738, 22640, 22738, 22738]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [152, 152, 152, 152],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048),',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [25524, 25964, 25964, 25964],
    'Evidence End': [26184, 26184, 26131, 26184]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [154, 154, 154, 154],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [26515, 26515, 26515, 26515],
    'Evidence End': [26703, 26703, 26703, 26703]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [125, 125, 125, 125],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [19128, 1469, 1469, 1469],
    'Evidence End': [19377, 1756, 1756, 1756]},
   {'UserID': [0, 3],
    'PromptID': [121, 121],
    'PMCID': [2871176, 2871176],
    'Valid Label': [True, True],
    'Valid Reasoning': [True, True],
    'Label': ['significantly increased', 'significantly increased'],
    'Annotations': ['The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). '],
    'Label Code': [1, 1],
    'In Abstract': [True, True],
    'Evidence Start': [18230, 18230],
    'Evidence End': [18670, 18476]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [124, 124, 124, 124],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001)',
     'reatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.',
     'Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001) ',
     'Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â€“2.4 mmol/l; P &lt; 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [19128, 19129, 19128, 19128],
    'Evidence End': [19251, 19377, 19252, 19377]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [107, 107, 107, 107],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (âˆ’0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride.',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). ',
     'Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (âˆ’0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride. ',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone. Rosiglitazone also was superior to placebo (P &lt; 0.0001).  '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [843, 13756, 843, 13756],
    'Evidence End': [1081, 13955, 1082, 14426]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [105, 105, 105, 105],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) or rosiglitazone (âˆ’0.4%, P &lt; 0.0001, baseline 8.4%) when added to glimepiride.',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). ',
     'All liraglutide doses were superior to placebo (P &lt; 0.0001),',
     'All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001).'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [843, 13756, 14169, 14169],
    'Evidence End': [1081, 13955, 14229, 14313]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [133, 133, 133, 133],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). ',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20566, 20566, 20566, 20566],
    'Evidence End': [20726, 20728, 20726, 20728]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [103, 103, 103, 103],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l)',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1469, 1469, 1469, 1469],
    'Evidence End': [1691, 1756, 1692, 1756]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [126, 126, 126, 126],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05)',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [19433, 19433, 19433, 19433],
    'Evidence End': [19623, 19624, 19601, 19624]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [118, 118, 118, 118],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%).',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). ',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%)',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [18230, 18230, 18230, 18230],
    'Evidence End': [18475, 18476, 18474, 18476]},
   {'UserID': [0, 1, 2],
    'PromptID': [132, 132, 132],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). ',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). '],
    'Label Code': [-1, -1, -1],
    'In Abstract': [True, True, True],
    'Evidence Start': [20566, 20566, 20566],
    'Evidence End': [20726, 20728, 20728]},
   {'UserID': [0, 1, 1, 2],
    'PromptID': [122, 122, 122, 122],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). ',
     'The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [18230, 18230, 18476, 18230],
    'Evidence End': [18670, 18476, 18670, 18670]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [141, 141, 141, 141],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg)',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22039, 22039, 22039, 22039],
    'Evidence End': [22230, 22232, 22199, 22232]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [151, 151, 151, 151],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone',
     'Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [25524, 25964, 25964, 25964],
    'Evidence End': [26184, 26184, 26073, 26184]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [112, 112, 112, 112],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003)',
     'At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  ',
     'The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  ',
     'The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [16120, 15956, 16120, 15735],
    'Evidence End': [16353, 16449, 16449, 16449]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [153, 153, 153, 153],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.',
     'No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [26515, 26515, 26515, 26515],
    'Evidence End': [26703, 26703, 26703, 26703]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [102, 102, 102, 102],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P â‰¤ 0.006) after 26 weeks.  ',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1144, 1144, 17914, 1144],
    'Evidence End': [1468, 1468, 18061, 1468]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [129, 129, 129, 129],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [19433, 19433, 19433, 19433],
    'Evidence End': [19624, 19624, 19624, 19624]},
   {'UserID': [1, 2],
    'PromptID': [104, 104],
    'PMCID': [2871176, 2871176],
    'Valid Label': [True, True],
    'Valid Reasoning': [True, True],
    'Label': ['significantly decreased', 'significantly decreased'],
    'Annotations': ['Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). '],
    'Label Code': [-1, -1],
    'In Abstract': [True, True],
    'Evidence Start': [1469, 1469],
    'Evidence End': [1756, 1756]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [116, 116, 116, 116],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001)',
     'By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.',
     'At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001),',
     'At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone.'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [17606, 17497, 17606, 17606],
    'Evidence End': [17699, 17913, 17700, 17785]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [136, 136, 136, 136],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05),',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20728, 20728, 20728, 20728],
    'Evidence End': [20816, 20942, 20817, 20942]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [123, 123, 123, 123],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l)',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) ',
     'Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [âˆ’2.5 to âˆ’2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (âˆ’0.4 mmol/l, P &lt; 0.0001, baseline 12.7 mmol/l) or rosiglitazone (âˆ’1.8 mmol/l, P &lt; 0.05, baseline 13.0 mmol/l). '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1469, 1469, 1469, 1469],
    'Evidence End': [1691, 1756, 1692, 1756]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [135, 135, 135, 135],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05),',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20728, 20728, 20728, 20728],
    'Evidence End': [20816, 20942, 20817, 20941]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [139, 139, 139, 139],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['There were no significant differences between treatments for HOMA-IR.',
     'There were no significant differences between treatments for HOMA-IR.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2',
     'There were no significant differences between treatments for HOMA-IR.',
     'There were no significant differences between treatments for HOMA-IR.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20943, -1, 20943, 20943],
    'Evidence End': [21012, -1, 21012, 21012]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [101, 101, 101, 101],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l)',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001)',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1144, 1144, 17606, 1144],
    'Evidence End': [1396, 1468, 17699, 1468]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [99, 99, 99, 99],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%)',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). ',
     'Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (âˆ’1.1%, baseline 8.5%) compared with placebo (+0.2%, P &lt; 0.0001, baseline 8.4%) ',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001)'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [843, 13756, 843, 13756],
    'Evidence End': [1002, 13955, 1003, 14312]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [144, 144, 144, 144],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg).',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22039, 22039, 22039, 22039],
    'Evidence End': [22231, 22232, 22232, 22232]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [145, 145, 145, 145],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments.',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. ',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. ',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22232, 22232, 22232, 22232],
    'Evidence End': [22372, 22373, 22373, 22373]},
   {'UserID': [0, 1, 2],
    'PromptID': [147, 147, 147],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P &lt; 0.01).',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). ',
     'Changes in pulse for all doses of liraglutide were significant vs. placebo (P â‰¤ 0.002). '],
    'Label Code': [1, 1, 1],
    'In Abstract': [True, True, True],
    'Evidence Start': [22554, 22554, 22554],
    'Evidence End': [22738, 22642, 22642]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [117, 117, 117, 117],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg. An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P â‰¤ 0.006) after 26 weeks.  '],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1144, 1144, 1144, 17497],
    'Evidence End': [1468, 1468, 1468, 18061]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [143, 143, 143, 143],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg).',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). ',
     'Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â€“2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â€“2.3 mmHg). '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22039, 22039, 22039, 22039],
    'Evidence End': [22231, 22232, 22232, 22232]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [111, 111, 111, 111],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001)',
     ' The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  FIGURE 4',
     'At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo ',
     'The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [16120, 16119, 15956, 16120],
    'Evidence End': [16315, 16457, 16110, 16449]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [137, 137, 137, 137],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).'],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20728, 20728, 20728, 20728],
    'Evidence End': [20941, 20942, 20902, 20942]},
   {'UserID': [0, 1],
    'PromptID': [114, 114],
    'PMCID': [2871176, 2871176],
    'Valid Label': [True, True],
    'Valid Reasoning': [True, True],
    'Label': ['significantly increased', 'significantly increased'],
    'Annotations': ['The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).',
     'At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  '],
    'Label Code': [1, 1],
    'In Abstract': [True, True],
    'Evidence Start': [16120, 15956],
    'Evidence End': [16447, 16449]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [108, 108, 108, 108],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Liraglutide 0.6 mg was non-inferior to rosiglitazone',
     'All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.',
     'Liraglutide 0.6 mg was non-inferior to rosiglitazone',
     '. All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [14314, 14169, 14314, 14167],
    'Evidence End': [14366, 14367, 14366, 14367]},
   {'UserID': [0],
    'PromptID': [128],
    'PMCID': [2871176],
    'Valid Label': [True],
    'Valid Reasoning': [True],
    'Label': ['significantly increased'],
    'Annotations': ['The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone'],
    'Label Code': [1],
    'In Abstract': [True],
    'Evidence Start': [19433],
    'Evidence End': [19623]},
   {'UserID': [0, 1, 2],
    'PromptID': [134, 134, 134],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). ',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), '],
    'Label Code': [-1, -1, -1],
    'In Abstract': [True, True, True],
    'Evidence Start': [20566, 20566, 20566],
    'Evidence End': [20726, 20728, 20818]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [115, 115, 115, 115],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l)',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).',
     'At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P &lt; 0.0001)',
     'Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P &lt; 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P &lt; 0.006, baseline 9.9 mmol/l).'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [1144, 1144, 17606, 1144],
    'Evidence End': [1396, 1468, 17699, 1468]},
   {'UserID': [0, 1, 2],
    'PromptID': [127, 127, 127],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone',
     'he percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.',
     'The percentage of subjects with one, two or three PPG measurements &lt; 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P &lt; 0.05) but not rosiglitazone.'],
    'Label Code': [1, 1, 1],
    'In Abstract': [True, True, True],
    'Evidence Start': [19433, 19434, 19433],
    'Evidence End': [19623, 19624, 19624]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [131, 131, 131, 131],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). ',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02). ',
     'Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P â‰¤ 0.02)'],
    'Label Code': [-1, -1, -1, -1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20566, 20566, 20566, 20566],
    'Evidence End': [20726, 20728, 20728, 20726]},
   {'UserID': [0, 1, 1, 3, 2],
    'PromptID': [109, 109, 109, 109, 109],
    'PMCID': [2871176, 2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True, True],
    'Valid Reasoning': [True, True, True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['Rosiglitazone also was superior to placebo (P &lt; 0.0001)',
     'Rosiglitazone also was superior to placebo (P &lt; 0.0001).',
     ' The greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3aâ€“c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone. ',
     'Rosiglitazone also was superior to placebo (P &lt; 0.0001).',
     'Rosiglitazone also was superior to placebo (P &lt; 0.0001).'],
    'Label Code': [-1, -1, -1, -1, -1],
    'In Abstract': [True, True, True, True, True],
    'Evidence Start': [14368, 14368, 13678, 14368, 14368],
    'Evidence End': [14423, 14424, 14368, 14424, 14424]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [146, 146, 146, 146],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments.',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. ',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. ',
     'Reductions in diastolic blood pressure also occurred with all treatments (0.7â€“1.4 mmHg), with no significant differences between treatments. '],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [22232, 22232, 22232, 22232],
    'Evidence End': [22372, 22373, 22373, 22373]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [110, 110, 110, 110],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001)',
     'The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  ',
     'The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  ',
     'The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c &lt; 7.0% and â‰¤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P &lt; 0.0001) or rosiglitazone (Fig. 4; P â‰¤ 0.0003), with more patients reaching &lt; 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).  '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [16120, 15735, 16120, 15735],
    'Evidence End': [16315, 16449, 16449, 16449]},
   {'UserID': [1, 3, 2],
    'PromptID': [100, 100, 100],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly decreased',
     'significantly decreased',
     'significantly decreased'],
    'Annotations': ['After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). ',
     'After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) ',
     'HbA1c decreased rapidly with all doses of liraglutide when added to glimepiride compared with either rosiglitazone or placebo (i.e. glimepiride monotherapy), irrespective of previous therapy. The greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3aâ€“c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (âˆ’0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: âˆ’1.4% (1.6, âˆ’1.1); liraglutide 1.2 mg: âˆ’1.3% (1.5, âˆ’1.1); liraglutide 0.6 mg: âˆ’0.8% (âˆ’1.1, âˆ’0.6); rosiglitazone: âˆ’0.7% (âˆ’0.9, âˆ’0.4). All liraglutide doses were superior to placebo (P &lt; 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P &lt; 0.0001). '],
    'Label Code': [-1, -1, -1],
    'In Abstract': [True, True, True],
    'Evidence Start': [13756, 13756, 13487],
    'Evidence End': [13955, 13944, 14314]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [138, 138, 138, 138],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['no significant difference',
     'no significant difference',
     'no significant difference',
     'no significant difference'],
    'Annotations': ['HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)',
     'HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P &lt; 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).'],
    'Label Code': [0, 0, 0, 0],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [20728, 20728, 20728, 20728],
    'Evidence End': [20941, 20942, 20941, 20942]},
   {'UserID': [0, 1, 3, 2],
    'PromptID': [119, 119, 119, 119],
    'PMCID': [2871176, 2871176, 2871176, 2871176],
    'Valid Label': [True, True, True, True],
    'Valid Reasoning': [True, True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%).',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). ',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001)',
     'The percentage of subjects achieving FPG values between 5.0 mmol/l and â‰¤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P &lt; 0.001); and 1.8 mg (38%;P &lt; 0.001) compared with placebo (7%). '],
    'Label Code': [1, 1, 1, 1],
    'In Abstract': [True, True, True, True],
    'Evidence Start': [18230, 18230, 18230, 18230],
    'Evidence End': [18475, 18476, 18419, 18476]},
   {'UserID': [0, 3, 2],
    'PromptID': [130, 130, 130],
    'PMCID': [2871176, 2871176, 2871176],
    'Valid Label': [True, True, True],
    'Valid Reasoning': [True, True, True],
    'Label': ['significantly increased',
     'significantly increased',
     'significantly increased'],
    'Annotations': ['Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (âˆ’2.3 to âˆ’1.4 kg; P &lt; 0.0001)',
     'Changes in body weight with liraglutide 1.8 mg (âˆ’0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (âˆ’0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P &lt; 0.0001, baseline 80.6 kg)',
     'Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (âˆ’2.3 to âˆ’1.4 kg; P &lt; 0.0001), although there were no significant differences compared with placebo. '],
    'Label Code': [1, 1, 1],
    'In Abstract': [True, True, True],
    'Evidence Start': [19950, 1756, 19950],
    'Evidence End': [20145, 1979, 20217]}]}}
</code></pre>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#data-fields" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="data-fields">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Data Fields
	</span>
</h3>
<ul>
<li><code>PMCID</code> (<code>int</code>): ID to identify the articles.</li>
<li><code>Text</code> (<code>str</code>): Article text.</li>
<li><code>Prompts</code> (<code>dict</code>): Prompts and annotations with keys:<ul>
<li>'PromptID': Which prompt the doctor is answering.</li>
<li>'PMCID'</li>
<li>'Outcome': Represent the fill-in-the-blank input for the following prompt formed "With respect to outcome, characterize the reported difference between intervention and those receiving comparator".</li>
<li>'Intervention': Represent the fill-in-the-blank input for the following prompt formed "With respect to outcome, characterize the reported difference between intervention and those receiving comparator".</li>
<li>'Comparator': Represent the fill-in-the-blank input for the following prompt formed "With respect to outcome, characterize the reported difference between intervention and those receiving comparator".</li>
<li>'Annotations': The annotation files consist of the following headings: UserID, PromptID, PMCID, Valid Label, Valid Reasoning, Label, Annotations, Label Code, In Abstract, Start Evidence, End Evidence.</li>
</ul>
</li>
</ul>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#data-splits" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="data-splits">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Data Splits
	</span>
</h3>
<div class="max-w-full overflow-auto">
	<table>
		<thead><tr>
<th>name</th>
<th align="right">train</th>
<th align="right">validation</th>
<th align="right">test</th>
</tr>

		</thead><tbody><tr>
<td>1.1</td>
<td align="right">1931</td>
<td align="right">248</td>
<td align="right">240</td>
</tr>
<tr>
<td>2.0</td>
<td align="right">2690</td>
<td align="right">340</td>
<td align="right">334</td>
</tr>
</tbody>
	</table>
</div>
<h2 class="relative group flex items-center">
	<a rel="nofollow" href="#dataset-creation" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="dataset-creation">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Dataset Creation
	</span>
</h2>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#curation-rationale" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="curation-rationale">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Curation Rationale
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#source-data" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="source-data">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Source Data
	</span>
</h3>
<p>[More Information Needed]</p>
<h4 class="relative group flex items-center">
	<a rel="nofollow" href="#initial-data-collection-and-normalization" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="initial-data-collection-and-normalization">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Initial Data Collection and Normalization
	</span>
</h4>
<p>[More Information Needed]</p>
<h4 class="relative group flex items-center">
	<a rel="nofollow" href="#who-are-the-source-language-producers" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="who-are-the-source-language-producers">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Who are the source language producers?
	</span>
</h4>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#annotations" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="annotations">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Annotations
	</span>
</h3>
<p>[More Information Needed]</p>
<h4 class="relative group flex items-center">
	<a rel="nofollow" href="#annotation-process" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="annotation-process">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Annotation process
	</span>
</h4>
<p>[More Information Needed]</p>
<h4 class="relative group flex items-center">
	<a rel="nofollow" href="#who-are-the-annotators" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="who-are-the-annotators">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Who are the annotators?
	</span>
</h4>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#personal-and-sensitive-information" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="personal-and-sensitive-information">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Personal and Sensitive Information
	</span>
</h3>
<p>[More Information Needed]</p>
<h2 class="relative group flex items-center">
	<a rel="nofollow" href="#considerations-for-using-the-data" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="considerations-for-using-the-data">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Considerations for Using the Data
	</span>
</h2>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#social-impact-of-dataset" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="social-impact-of-dataset">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Social Impact of Dataset
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#discussion-of-biases" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="discussion-of-biases">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Discussion of Biases
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#other-known-limitations" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="other-known-limitations">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Other Known Limitations
	</span>
</h3>
<p>[More Information Needed]</p>
<h2 class="relative group flex items-center">
	<a rel="nofollow" href="#additional-information" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="additional-information">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Additional Information
	</span>
</h2>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#dataset-curators" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="dataset-curators">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Dataset Curators
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#licensing-information" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="licensing-information">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Licensing Information
	</span>
</h3>
<p>[More Information Needed]</p>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#citation-information" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="citation-information">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Citation Information
	</span>
</h3>
<pre><code>@inproceedings{lehman2019inferring,
  title={Inferring Which Medical Treatments Work from Reports of Clinical Trials},
  author={Lehman, Eric and DeYoung, Jay and Barzilay, Regina and Wallace, Byron C},
  booktitle={Proceedings of the North American Chapter of the Association for Computational Linguistics (NAACL)},
  pages={3705--3717},
  year={2019}
}

@misc{deyoung2020evidence,
    title={Evidence Inference 2.0: More Data, Better Models},
    author={Jay DeYoung and Eric Lehman and Ben Nye and Iain J. Marshall and Byron C. Wallace},
    year={2020},
    eprint={2005.04177},
    archivePrefix={arXiv},
    primaryClass={cs.CL}
}
</code></pre>
<h3 class="relative group flex items-center">
	<a rel="nofollow" href="#contributions" class="block pr-1.5 text-lg md:absolute md:p-1.5 md:opacity-0 md:group-hover:opacity-100 md:right-full" id="contributions">
		<span class="header-link"><svg viewBox="0 0 256 256" preserveAspectRatio="xMidYMid meet" height="1em" width="1em" role="img" aria-hidden="true" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" class="text-gray-500 hover:text-black dark:hover:text-gray-200 w-4"><path fill="currentColor" d="M167.594 88.393a8.001 8.001 0 0 1 0 11.314l-67.882 67.882a8 8 0 1 1-11.314-11.315l67.882-67.881a8.003 8.003 0 0 1 11.314 0zm-28.287 84.86l-28.284 28.284a40 40 0 0 1-56.567-56.567l28.284-28.284a8 8 0 0 0-11.315-11.315l-28.284 28.284a56 56 0 0 0 79.196 79.197l28.285-28.285a8 8 0 1 0-11.315-11.314zM212.852 43.14a56.002 56.002 0 0 0-79.196 0l-28.284 28.284a8 8 0 1 0 11.314 11.314l28.284-28.284a40 40 0 0 1 56.568 56.567l-28.285 28.285a8 8 0 0 0 11.315 11.314l28.284-28.284a56.065 56.065 0 0 0 0-79.196z"></path></svg></span>
	</a>
	<span>
		Contributions
	</span>
</h3>
<p>Thanks to <a rel="nofollow" href="https://github.com/Narsil">@Narsil</a> for adding this dataset.</p>
<!-- HTML_TAG_END --></div>
</div></section>
			
			<section class="pt-6 border-gray-100 md:pb-24 md:pl-6 md:w-64 lg:w-80 xl:w-96 flex-none order-first md:order-none md:border-l pt-3! md:pt-6!"><dl class="flex items-baseline justify-between"><dt class="text-sm text-gray-500">Downloads last month</dt><div class="mx-4 flex-1 border-b border-dotted"></div><dd class="font-semibold">183</dd></dl>
				
				<div class="divider-column-vertical"></div>
				<div class="grid grid-cols-2 gap-x-2 md:flex md:flex-row md:flex-wrap"><div class="SVELTE_HYDRATER contents" data-target="DatasetAndModelActionsDropdown" data-props="{&quot;classNames&quot;:&quot;order-last&quot;,&quot;discussionsDisabled&quot;:false,&quot;repo&quot;:{&quot;type&quot;:&quot;dataset&quot;,&quot;name&quot;:&quot;jaydeyoung/evidence_infer_treatment&quot;},&quot;canWrite&quot;:false,&quot;canDisable&quot;:false,&quot;repoIsPrivate&quot;:false,&quot;repoIsGated&quot;:false,&quot;repoIsDisabled&quot;:false,&quot;repoIsAdminFlaggedNFAA&quot;:false,&quot;repoHasBlockedOids&quot;:false}"><div class="order-last"><div class="relative ">
	<button class="btn px-1.5 py-1.5 " type="button">
		
			<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" aria-hidden="true" role="img" class="p-0.5" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><circle cx="16" cy="7" r="3" fill="currentColor"></circle><circle cx="16" cy="16" r="3" fill="currentColor"></circle><circle cx="16" cy="25" r="3" fill="currentColor"></circle></svg>
		
		</button>
	
	
	</div></div>













</div>
					<div class="SVELTE_HYDRATER contents" data-target="DatasetLibrary" data-props="{&quot;classNames&quot;:&quot;md:w-full xl:w-auto xl:flex-none&quot;}">

</div>
					
					</div>
				<div class="divider-column-vertical"></div>
					<div class="flex flex-col flex-wrap xl:flex-row"><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 " href="http://evidence-inference.ebm-nlp.com/" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Homepage:</div>
		<div class="truncate text-sm group-hover:underline">
			<!-- HTML_TAG_START -->evidence-inference.ebm-nlp.com<!-- HTML_TAG_END --></div></a><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 " href="https://github.com/jayded/evidence-inference" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Repository:</div>
		<div class="truncate text-sm group-hover:underline">
			<!-- HTML_TAG_START -->github.com<!-- HTML_TAG_END --></div></a><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 " href="https://arxiv.org/abs/2005.04177" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Paper:</div>
		<div class="truncate text-sm group-hover:underline">
			<!-- HTML_TAG_START -->Evidence Inference 2.0: More Data, Better Models<!-- HTML_TAG_END --></div></a><a class="bg-linear-to-r dark:via-none group mb-1.5 flex max-w-full flex-col overflow-hidden rounded-lg border border-gray-100 from-white via-white to-white px-2 py-1 hover:from-gray-50 dark:from-gray-900 dark:to-gray-925 dark:hover:to-gray-900 md:mr-1.5 " href="http://evidence-inference.ebm-nlp.com/leaderboard/" rel="nofollow" target="_blank"><div class="truncate text-xs text-gray-400">Leaderboard:</div>
		<div class="truncate text-sm group-hover:underline">
			<!-- HTML_TAG_START -->evidence-inference.ebm-nlp.com<!-- HTML_TAG_END --></div></a></div>
				
				
				
				

				
				<div class="divider-column-vertical md:hidden"></div></section></div></main>

	<footer class="b-12 mb-2 flex border-t border-gray-100 md:h-14"><nav class="container relative flex flex-col justify-between space-y-2 py-6 text-gray-500 max-md:*:self-start md:flex-row md:items-center md:space-y-0 md:py-0 md:text-sm"><div class="SVELTE_HYDRATER contents" data-target="ThemeSwitcher" data-props="{&quot;theme&quot;:&quot;system&quot;,&quot;isLoggedIn&quot;:false,&quot;menuClassNames&quot;:&quot;md:-top-24&quot;,&quot;classNames&quot;:&quot;max-md:mb-5 max-md:*:self-start&quot;}">
<div class="relative inline-block max-md:mb-5 max-md:*:self-start">
	<button class="rounded-full border border-gray-100 pl-2 py-1 pr-2.5  flex items-center text-sm text-gray-500 bg-white hover:bg-purple-50 hover:border-purple-200 dark:hover:bg-gray-800 dark:hover:border-gray-950 dark:border-gray-800 " type="button">
		<svg class="mr-1.5 text-gray-500" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" fill="currentColor" focusable="false" role="img" width="1em" height="1em" preserveAspectRatio="xMidYMid meet" viewBox="0 0 32 32"><path d="M29 25H3a1 1 0 1 0 0 2h26a1 1 0 1 0 0-2Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M6 22.5h20a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2H6a2 2 0 0 0-2 2v13.5a2 2 0 0 0 2 2ZM7 7a1 1 0 0 0-1 1v11a1 1 0 0 0 1 1h18a1 1 0 0 0 1-1V8a1 1 0 0 0-1-1H7Z" fill="currentColor"></path><path d="M6 8a1 1 0 0 1 1-1h18a1 1 0 0 1 1 1v11a1 1 0 0 1-1 1H7a1 1 0 0 1-1-1V8Z" fill="currentColor" fill-opacity=".4"></path><path d="M29 25H3a1 1 0 1 0 0 2h26a1 1 0 1 0 0-2Z" fill="currentColor"></path></svg>
			System theme
		</button>
	
	
	</div></div>
		<div class="font-semibold text-black md:hidden">Company</div>
		<a class="hover:underline" href="/terms-of-service">TOS</a>
		<a class="hover:underline" href="/privacy">Privacy</a>
		<a class="hover:underline" href="/huggingface">About</a>
		<a class="hover:underline" href="https://apply.workable.com/huggingface/">Jobs</a>
		<a href="/" class="max-md:mb-4! max-md:mt-8! group flex-none max-md:order-last"><svg class="h-7 w-7 transition-transform group-hover:-translate-y-px" viewBox="0 0 95 88" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M47.2119 76.5C66.4037 76.5 81.9619 60.9419 81.9619 41.75C81.9619 22.5581 66.4037 7 47.2119 7C28.02 7 12.4619 22.5581 12.4619 41.75C12.4619 60.9419 28.02 76.5 47.2119 76.5Z" fill="#FFD21E"></path><path d="M81.9619 41.75C81.9619 22.5581 66.4037 7 47.2119 7C28.02 7 12.4619 22.5581 12.4619 41.75C12.4619 60.9419 28.02 76.5 47.2119 76.5C66.4037 76.5 81.9619 60.9419 81.9619 41.75ZM8.46185 41.75C8.46185 20.349 25.8108 3 47.2119 3C68.6129 3 85.9619 20.349 85.9619 41.75C85.9619 63.151 68.6129 80.5 47.2119 80.5C25.8108 80.5 8.46185 63.151 8.46185 41.75Z" fill="#FF9D0B"></path><path d="M58.5024 32.2915C59.7768 32.7415 60.2839 35.3615 61.5713 34.6769C64.0095 33.3805 64.9351 30.353 63.6387 27.9148C62.3423 25.4767 59.3148 24.5511 56.8766 25.8475C54.4384 27.1439 53.5128 30.1714 54.8092 32.6096C55.4211 33.7604 57.3632 31.8892 58.5024 32.2915Z" fill="#3A3B45"></path><path d="M34.9454 32.2915C33.671 32.7415 33.164 35.3615 31.8766 34.6769C29.4384 33.3805 28.5128 30.353 29.8092 27.9148C31.1056 25.4767 34.1331 24.5511 36.5713 25.8475C39.0095 27.1439 39.9351 30.1714 38.6387 32.6096C38.0268 33.7604 36.0846 31.8892 34.9454 32.2915Z" fill="#3A3B45"></path><path d="M46.9619 56.289C56.7903 56.289 59.9619 47.5261 59.9619 43.0262C59.9619 40.6875 58.3898 41.4236 55.8718 42.6702C53.5449 43.8222 50.4102 45.4101 46.9619 45.4101C39.7822 45.4101 33.9619 38.5263 33.9619 43.0262C33.9619 47.5261 37.1334 56.289 46.9619 56.289Z" fill="#3A3B45"></path><mask id="mask0" style="mask-type:alpha" maskUnits="userSpaceOnUse" x="33" y="41" width="27" height="16"><path d="M46.9619 56.289C56.7903 56.289 59.9619 47.5261 59.9619 43.0262C59.9619 40.6875 58.3898 41.4236 55.8718 42.6702C53.5449 43.8222 50.4102 45.4101 46.9619 45.4101C39.7822 45.4101 33.9619 38.5263 33.9619 43.0262C33.9619 47.5261 37.1334 56.289 46.9619 56.289Z" fill="white"></path></mask><g mask="url(#mask0)"><path d="M47.2119 66.5C52.0018 66.5 55.8848 62.617 55.8848 57.8271C55.8848 54.0962 53.5291 50.9156 50.224 49.6915C50.1023 49.6464 49.9794 49.604 49.8553 49.5643C49.0219 49.2979 48.1337 52.1623 47.2119 52.1623C46.3506 52.1623 45.5186 49.2797 44.7332 49.5135C41.151 50.5799 38.5389 53.8984 38.5389 57.8271C38.5389 62.617 42.4219 66.5 47.2119 66.5Z" fill="#F94040"></path></g><path d="M70.7119 37C72.5068 37 73.9619 35.5449 73.9619 33.75C73.9619 31.9551 72.5068 30.5 70.7119 30.5C68.9169 30.5 67.4619 31.9551 67.4619 33.75C67.4619 35.5449 68.9169 37 70.7119 37Z" fill="#FF9D0B"></path><path d="M24.2119 37C26.0068 37 27.4619 35.5449 27.4619 33.75C27.4619 31.9551 26.0068 30.5 24.2119 30.5C22.4169 30.5 20.9619 31.9551 20.9619 33.75C20.9619 35.5449 22.4169 37 24.2119 37Z" fill="#FF9D0B"></path><path class="origin-bottom-right transition-transform group-hover:-rotate-6" d="M17.5238 48C15.9048 48 14.4578 48.665 13.4488 49.871C12.8248 50.618 12.1728 51.822 12.1198 53.625C11.4408 53.43 10.7878 53.321 10.1778 53.321C8.6278 53.321 7.2278 53.915 6.2378 54.994C4.9658 56.379 4.4008 58.081 4.6468 59.784C4.7638 60.595 5.0348 61.322 5.4398 61.995C4.5858 62.686 3.9568 63.648 3.6528 64.805C3.4148 65.712 3.1708 67.601 4.4448 69.547C4.3638 69.674 4.2878 69.806 4.2168 69.941C3.4508 71.395 3.4018 73.038 4.0778 74.568C5.1028 76.887 7.6498 78.714 12.5958 80.675C15.6728 81.895 18.4878 82.675 18.5128 82.682C22.5808 83.737 26.2598 84.273 29.4448 84.273C35.2988 84.273 39.4898 82.48 41.9018 78.944C45.7838 73.25 45.2288 68.042 40.2058 63.022C37.4258 60.244 35.5778 56.148 35.1928 55.249C34.4168 52.587 32.3648 49.628 28.9538 49.628H28.9528C28.6658 49.628 28.3758 49.651 28.0898 49.696C26.5958 49.931 25.2898 50.791 24.3568 52.085C23.3498 50.833 22.3718 49.837 21.4868 49.275C20.1528 48.429 18.8198 48 17.5238 48ZM17.5238 52C18.0338 52 18.6568 52.217 19.3438 52.653C21.4768 54.006 25.5928 61.081 27.0998 63.833C27.6048 64.755 28.4678 65.145 29.2448 65.145C30.7868 65.145 31.9908 63.612 29.3858 61.664C25.4688 58.733 26.8428 53.942 28.7128 53.647C28.7948 53.634 28.8758 53.628 28.9538 53.628C30.6538 53.628 31.4038 56.558 31.4038 56.558C31.4038 56.558 33.6018 62.078 37.3778 65.851C41.1538 69.625 41.3488 72.654 38.5968 76.69C36.7198 79.442 33.1268 80.273 29.4448 80.273C25.6258 80.273 21.7108 79.379 19.5168 78.81C19.4088 78.782 6.0658 75.013 7.7558 71.805C8.0398 71.266 8.5078 71.05 9.0968 71.05C11.4768 71.05 15.8058 74.592 17.6668 74.592C18.0828 74.592 18.3758 74.415 18.4958 73.983C19.2888 71.138 6.4388 69.942 7.5218 65.821C7.7128 65.092 8.2308 64.796 8.9588 64.797C12.1038 64.797 19.1598 70.328 20.6388 70.328C20.7518 70.328 20.8328 70.295 20.8768 70.225C21.6178 69.029 21.2118 68.194 15.9888 65.033C10.7658 61.871 7.0998 59.969 9.1848 57.699C9.4248 57.437 9.7648 57.321 10.1778 57.321C13.3488 57.322 20.8408 64.14 20.8408 64.14C20.8408 64.14 22.8628 66.243 24.0858 66.243C24.3668 66.243 24.6058 66.132 24.7678 65.858C25.6348 64.396 16.7148 57.636 16.2118 54.847C15.8708 52.957 16.4508 52 17.5238 52Z" fill="#FF9D0B"></path><path class="origin-bottom-right transition-transform group-hover:-rotate-6" d="M38.5967 76.6898C41.3487 72.6538 41.1537 69.6248 37.3777 65.8508C33.6017 62.0778 31.4037 56.5578 31.4037 56.5578C31.4037 56.5578 30.5827 53.3518 28.7127 53.6468C26.8427 53.9418 25.4697 58.7328 29.3867 61.6638C33.3037 64.5938 28.6067 66.5848 27.0997 63.8328C25.5927 61.0808 21.4777 54.0058 19.3437 52.6528C17.2107 51.2998 15.7087 52.0578 16.2117 54.8468C16.7147 57.6358 25.6357 64.3958 24.7677 65.8588C23.8997 67.3208 20.8407 64.1398 20.8407 64.1398C20.8407 64.1398 11.2687 55.4288 9.18465 57.6988C7.10065 59.9688 10.7657 61.8708 15.9887 65.0328C21.2127 68.1938 21.6177 69.0288 20.8767 70.2248C20.1347 71.4208 8.60465 61.6998 7.52165 65.8208C6.43965 69.9418 19.2887 71.1378 18.4957 73.9828C17.7027 76.8288 9.44465 68.5978 7.75565 71.8048C6.06565 75.0128 19.4087 78.7818 19.5167 78.8098C23.8267 79.9278 34.7727 82.2968 38.5967 76.6898Z" fill="#FFD21E"></path><path class="origin-bottom-left transition-transform group-hover:rotate-6" d="M77.3999 48C79.0189 48 80.4659 48.665 81.4749 49.871C82.0989 50.618 82.7509 51.822 82.8039 53.625C83.4829 53.43 84.1359 53.321 84.7459 53.321C86.2959 53.321 87.6959 53.915 88.6859 54.994C89.9579 56.379 90.5229 58.081 90.2769 59.784C90.1599 60.595 89.8889 61.322 89.4839 61.995C90.3379 62.686 90.9669 63.648 91.2709 64.805C91.5089 65.712 91.7529 67.601 90.4789 69.547C90.5599 69.674 90.6359 69.806 90.7069 69.941C91.4729 71.395 91.5219 73.038 90.8459 74.568C89.8209 76.887 87.2739 78.714 82.3279 80.675C79.2509 81.895 76.4359 82.675 76.4109 82.682C72.3429 83.737 68.6639 84.273 65.4789 84.273C59.6249 84.273 55.4339 82.48 53.0219 78.944C49.1399 73.25 49.6949 68.042 54.7179 63.022C57.4979 60.244 59.3459 56.148 59.7309 55.249C60.5069 52.587 62.5589 49.628 65.9699 49.628H65.9709C66.2579 49.628 66.5479 49.651 66.8339 49.696C68.3279 49.931 69.6339 50.791 70.5669 52.085C71.5739 50.833 72.5519 49.837 73.4369 49.275C74.7709 48.429 76.1039 48 77.3999 48ZM77.3999 52C76.8899 52 76.2669 52.217 75.5799 52.653C73.4469 54.006 69.3309 61.081 67.8239 63.833C67.3189 64.755 66.4559 65.145 65.6789 65.145C64.1369 65.145 62.9329 63.612 65.5379 61.664C69.4549 58.733 68.0809 53.942 66.2109 53.647C66.1289 53.634 66.0479 53.628 65.9699 53.628C64.2699 53.628 63.5199 56.558 63.5199 56.558C63.5199 56.558 61.3219 62.078 57.5459 65.851C53.7699 69.625 53.5749 72.654 56.3269 76.69C58.2039 79.442 61.7969 80.273 65.4789 80.273C69.2979 80.273 73.2129 79.379 75.4069 78.81C75.5149 78.782 88.8579 75.013 87.1679 71.805C86.8839 71.266 86.4159 71.05 85.8269 71.05C83.4469 71.05 79.1179 74.592 77.2569 74.592C76.8409 74.592 76.5479 74.415 76.4279 73.983C75.6349 71.138 88.4849 69.942 87.4019 65.821C87.2109 65.092 86.6929 64.796 85.9649 64.797C82.8199 64.797 75.7639 70.328 74.2849 70.328C74.1719 70.328 74.0909 70.295 74.0469 70.225C73.3059 69.029 73.7119 68.194 78.9349 65.033C84.1579 61.871 87.8239 59.969 85.7389 57.699C85.4989 57.437 85.1589 57.321 84.7459 57.321C81.5749 57.322 74.0829 64.14 74.0829 64.14C74.0829 64.14 72.0609 66.243 70.8379 66.243C70.5569 66.243 70.3179 66.132 70.1559 65.858C69.2889 64.396 78.2089 57.636 78.7119 54.847C79.0529 52.957 78.4729 52 77.3999 52Z" fill="#FF9D0B"></path><path class="origin-bottom-left transition-transform group-hover:rotate-6" d="M56.3271 76.6898C53.5751 72.6538 53.7701 69.6248 57.5461 65.8508C61.3221 62.0778 63.5201 56.5578 63.5201 56.5578C63.5201 56.5578 64.3411 53.3518 66.2111 53.6468C68.0811 53.9418 69.4541 58.7328 65.5371 61.6638C61.6201 64.5938 66.3171 66.5848 67.8241 63.8328C69.3311 61.0808 73.4461 54.0058 75.5801 52.6528C77.7131 51.2998 79.2151 52.0578 78.7121 54.8468C78.2091 57.6358 69.2881 64.3958 70.1561 65.8588C71.0241 67.3208 74.0831 64.1398 74.0831 64.1398C74.0831 64.1398 83.6551 55.4288 85.7391 57.6988C87.8231 59.9688 84.1581 61.8708 78.9351 65.0328C73.7111 68.1938 73.3061 69.0288 74.0471 70.2248C74.7891 71.4208 86.3191 61.6998 87.4021 65.8208C88.4841 69.9418 75.6351 71.1378 76.4281 73.9828C77.2211 76.8288 85.4791 68.5978 87.1681 71.8048C88.8581 75.0128 75.5151 78.7818 75.4071 78.8098C71.0971 79.9278 60.1511 82.2968 56.3271 76.6898Z" fill="#FFD21E"></path></svg></a>
		<div class="max-md:mt-8! font-semibold text-black md:hidden">Website</div>

		<a class="hover:underline" href="/models">Models</a>
		<a class="hover:underline" href="/datasets">Datasets</a>
		<a class="hover:underline" href="/spaces">Spaces</a>
		<a class="hover:underline" href="/pricing">Pricing</a>
		<a class="hover:underline" href="/docs">Docs</a></nav></footer></div>

		<script>
			import("\/front\/build\/kube-68d7aa0\/index.js");
			window.moonSha = "kube-68d7aa0\/";
			window.__hf_deferred = {};
		</script>

		<!-- Stripe -->
		<script>
			if (["hf.co", "huggingface.co"].includes(window.location.hostname)) {
				const script = document.createElement("script");
				script.src = "https://js.stripe.com/v3/";
				script.async = true;
				document.head.appendChild(script);
			}
		</script>
	</body>
</html>
